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Hemanth K. Mamidi 
 
 
The major challenges in the formulation of amorphous solid dispersions (ASDs) 
using hot-melt extrusion (HME) are the selection of an ideal polymeric carrier, 
optimization of HME processing conditions, and screening of the physical stability of the 
ASDs. Addressing these challenges using traditional approaches require extensive 
experimentation and large amounts of active pharmaceutical ingredients (API) which 
may not be feasible during the initial stages of product development. Therefore, there is a 
need to develop material-sparing techniques for the successful formulation of ASDs. The 
objective of the present study was to develop material-sparing techniques that can be 
used as pre-formulation tool during the formulation of ASDs. For this purpose, 
mefenamic acid (MFA) was used as a model drug and four chemically distinct polymers 
with close values of the solubility parameters, viz. Kollidon® VA64, Soluplus®, Pluronic® 
F68, and Eudragit® EPO, were used as polymeric carriers. The selection of an ideal 
polymer was carried out based on the solubility parameter approach, melting point 
depression method, thermodynamic phase diagrams, and Gibbs free energy plots. Then 
the HME processing conditions were determined based on a material-sparing technique 
using differential scanning calorimeter (DSC). The physical stability of the ASDs was 
estimated using the modified Avarami equation. Based on the results of the melting point 




was found to be an ideal polymer for the preparation of amorphous solid dispersion 
formulation of mefenamic acid. The design space for HME determined using DSC 
method showed that when 20% drug loaded MFA-EPO blends was heated at a rate of 5.5 
°C/min to a temperature of 146 °C, the resulting ASD contained a residual crystallinity of 
13.6% and drug degradation of 3.8%. The physical stability of the MFA-EPO ASDs 
determined using a modified Avarami equation showed that the rate of recrystallization 
changed significantly with the change in process temperature as compared to the change 
in the relative humidity. The study results show that the time frame and experiments 
required in the formulation of ASDs can be significantly reduced by using the material-
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Poor aqueous solubility of drugs is one of the major challenges in the 
pharmaceutical industry. Enhancing the oral bioavailability of poorly aqueous soluble 
drugs by improving their solubility remains one of most challenging aspects of drug 
development process. Various traditional and newer approaches have been developed to 
improve the solubility of poory water soluble drugs. The traditional methods include 
solid dispersion, complexation and pH adjustment while newer methods include 
liquisolid technology, hydrotropy, lipid-based system, etc. The choice of technique is 
selected based on the properties of drug, nature of excipients and the intended dosage 
form. Out of all the techniques to improve solubility, solid dispersion formulation 
remains one of the widely used technique due to its simplicity and ease of 
commercialization. 
 
1.1. Solid Dispersions 
Sekiguchi and Obi in 1961 first proposed the concept of solid dispersions (1). 
They described solid dispersions as the biphasic systems of drug particles dispersed in a 
polymeric carrier. Over the decades, various other definitions of solid dispersions were 
proposed. Most recently, Janssens et al. defined solid dispersions as, “Formulations of 
poorly-soluble compounds which might lead to particle size reduction, improved wetting, 
reduced agglomeration, changes in the physical state of the drug and possibly dispersion 
on a molecular level, according to the physical state of the solid dispersions that depends 
on the physicochemical properties of carrier and the drug, the drug-carrier interaction and 




basis of the crystalline nature of the drug molecules and their distribution in the carrier 
matrix as shown in Table 1. Type I solid dispersions are eutectic mixtures in a specific 
ratio and have a single melting point which is lower than the melting point of the 
individual components. Type II solid dispersions are amorphous precipitates in 
crystalline matrix where the drug is present in amorphous form dispersed in crystalline 
polymeric matrix. Type III solid solutions are similar to Type II but the drug is 
molecularly dispersed in the polymeric carrier. It can be either monophasic or biphasic. 
In type IV, V and VI solid dispersions, the drug is either in crystalline, amorphous or 
molecularly dispersed form, respectively in an amorphous polymeric matrix.  To obtain a 
glassy solution, the drug should be completely miscible in the polymeric matrix.  Type 
IV, V and VI solid dispersions are prominent now a days and are prepared using spray-
drying or hot-melt extrusion technique.  Type IV is achieved if the drug is dispersed as 
crystals in the amorphous polymer phase. This is a two-phase system in which the 
melting endotherm of the drug and the glass transition temperature of the polymer are 
obtained when the drug-polymer blend is subjected to DSC analysis. In type V solid 
dispersions, the drug is transformed into amorphous state but is not molecularly dispersed 
in the polymer matrix. In case of type VI, the solid dispersion of the drug is molecularly 
dispersed in the polymer phase. This results in a single-phase system showing only one 
glass transition temperature. 
To better understand the difference in the thermodynamic properties of a 
crystalline and an amorphous form, consider a crystalline drug that is heated to ceratin 
temperature where it melts completely. Upon slowly cooling, the drug molecules form an 




the cooling rate is high, then the drug molecules may attain a supercooled liquid state 
without undergoing crystallization. On further cooling, a glass transition temperature (Tg) 
is reached below which it converts into a frozen glassy state. A material in a glassy state 
behaves like a brittle solid but without crystalline structure (4). The amorphous state of a 
drug has a higher enthalpy, entropy and Gibbs free energy as compared with the 
crystalline form. This is the reason why amorphous drug has higher apparent solubility. 
When an amorphous drug is added to the dissolution media, the drug solubilizes rapidly 
forming a supersaturated solution followed by a decrease in solubility due to 
devitrification. This phenomenon is known as “spring and parachute effect” and creates 
considerable challenges during dissolution. The choice of the polymeric carrier plays a 
major role in maintaining the supersaturated solution and preventing the spring and 
parachute effect during dissolution. Therefore, the selection of a polymeric carrier plays a 





Table 1: Various types of solid dispersions based on the physicochemical properties of 
the drug and the carrier 
Type of solid dispersion Matrix Drug Phases 
I. Eutectic C C 2 
II. Amorphous precipitates in crystalline matrix C A 2 
III. Solid solutions C M 1 or 2 
IV. Glassy suspensions A C 2 
V. Glassy suspensions A A 2 
VI. Glassy solutions A M 1 
 





1.2. Various Polymeric Carriers for ASDs 
Polymers are repetitive structural units of monomers which are linked with each 
other. They can be classified on the basis of their origin as natural, semisynthetic or 
synthetic polymers (5). Polymers are classified as homopolymers (one type of monomer) 
or a copolymer (two monomers). Polymers can be amorphous, semicrystalline or 
crystalline. Since polymers have a complex 3-dimensional structure, incorporation of 
amorphous drugs into the polymeric matrix hinders the molecular mobility of amorphous 
drug, thereby preventing recrystallization over the shelf life of the product (6). The 
physical and chemical stability of ASDs depend on various factors like molecular 
mobility, thermodynamic properties, environmental stress, and method of preparation. 
The polymeric carriers will effects these factors and stabilize the ASDs by four main 
mechanisms: 
 Crystallization inhibition 
 Antiplastisization  
 Intermolecular interactions 
 Reduction of molecular mobility 
 
1.2.1. Crystallization Inhibition 
The crystallization of an amorphous drug is a 2-step process that occur 
simultaneously. The first step is nucleation and occurs at a lower temperature, and the 
second step is the crystal growth that requires higher temperatures (2). Thus, nucleation 
may not start until a certain degree of supersaturation is reached to overcome the energy 




metastable zone. An ideal polymeric excipient increases the degree of supersaturation, 
thus expands the metastable region. Polymeric excipients that increase aqueous solubility 
can retard the nucleation rate by decreasing the free drug concentration available for 
nuclei/ seed formation (7). Since polymeric carriers have sufficiently high configurational 
entropy due to their large, complex, and flexible structures, they significantly reduce the 




Antiplasticization is described as a phenomenon which leads to an increase in 
glass transition temperature, Tg of the material. This results in an increase in the free 
energy required by the amorphous drug to convert into the crystalline form (8). When 
two materials having different Tg are mixed together, the final Tg of the mixture will be 
somewhere between the Tg of both the materials. Mixing a low Tg amorphous drug with a 
high Tg polymer at the molecular level leads to the formation of ASDs with a Tg 
intermediate of these two components. In other words, the polymer undergoes 
plasticization whereas the Tg of the drug increases, and it undergoes antiplasticization. 
Sathigari et al. have studied the stabilization of amorphous efavirenz in Plasdone S-630 
carrier (9). They have reported that the stability of the amorphous efavirenz in the solid 
dispersion is due to the antiplasticizing effect of the polymer which increased the 




1.2.3. Intermolecular Interaction 
The drug molecules may interact with polymers by several weak forces such as 
hydrogen bonding, van der Waals forces, electrostatic, ionic, or hydrophobic interactions 
(10). These intermolecular bonds restrict the molecular mobility of the drug molecules in 
the polymer matrix and increases the physical stability of the drug-polymer system (11). 
Meng et al. highlighted the importance of drug-polymer interactions in the stability of 
amorphous curcumin as a model drug (12). They examined the ability of different 
polymers, such as PVP K90, Eudragit EPO®, HPMC, and PEG 8000, to interact with the 
model drug through stable bond formation. It was concluded that a certain degree of 
interaction between a drug and a polymer is important for successful formulation of 
ASDs. Maniruzzaman et al. have reported that the drug polymer ratio and miscibility 
defines the magnitude of the intermolecular interactions (13).  
 
1.2.4. Reduction of Molecular Mobility 
The molecular mobility of amorphous materials determines their physical 
stability. Polymeric carriers have the capacity to restrict the molecular mobility of the 
amorphous API which can be determined using certain analytical techniques like 
differential scanning calorimeter (DSC), solid-state nuclear magnetic resonance 
(ssNMR), and dielectric spectroscopy. Knapik et al. have shown that the physical 
stability and water solubility of the amorphous ezetimibe was improved over 6 times 
when mixed within a ASD using Soluplus® as carrier (14). DSC and dielectric 
spectroscopy analysis of amorphous ezetimibe have led to the conclusion that the high 




crystallization tendency. This indicates that formation of ASDs in the Soluplus® matrix 
acts as physical barrier to the molecular motions of glass ezetimibe leading to improved 
stability. In another study, Kothari et al. reported that the relaxation time of the drug 
increases with an increase in polymer concentration (15).  
 
1.3. Preparation of ASDs using Hot Melt Extruion 
The pharmaceutical industry is shifting from the traditional spray drying process 
towards hot-melt extrusion for the preparation of solid dispersions.  This is to reduce the 
use of solvents and also to achieve the goal of continuous manufacturing. Hot-melt 
extrusion (HME) has been revealed as a viable technology for variety of applications in 
the pharmaceutical industry (16). The enhancement of solubility and bioavailability 
through the manufacturing of ASDs is the primary use of HME, as indicated by the 
multiple papers and patents. Current, interest in the formulation of ASDs using HME is 
growing rapidly with a number of papers published in the scientific literature during the 
past two decade (9, 17-19). Although there is a huge potential for formulating poorly 
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This can be attributed to the poor understanding of the ASD formulations at the 
molecular level and also the trial and error approach employed for HME (Fig. 1). 
However, with an increase in the number of some high quality research in the field of 
ASDs, more and more scientific data is available to understand the drug-polymer 
interactions and the effect of the HME process on the performance of ASDs. This is 
evident as more and more HME-based drug products appear in the pipeline of many 
pharmaceutical companies. Lately, there have been new product submissions to the FDA 
and to the European Medicines Agency (EMA) (19). In HME-based drug products, a 
robust preformulation assessment is the key to a successful development. A step-by-step 
approach, starting with the thermodynamic evaluation of several systems, followed by a 
polymer screening test is useful to rapidly identify optimized HME formulations. The 
three main aspects of developing ASDs are: 
 Rationale selection of polymer 
 Process design and optimization 
















1.4. Rationale Selection of Polymeric carrier 
The rationale for the selection of polymer has been largely its glass transition 
temperature (Tg), melt viscosity and dissolution rate. Polymers with high glass transition 
temperature Tg are generally used to prepare ASDs owing to their antiplasticizing effect 
that reduces the molecular mobility of amorphous drug. However, when there is no Tg 
differences between amorphous drug and the solid dispersion, then the drug-polymer 
interactions will determine the shelf life of ASDs (20). Increasing the molecular weight 
raises the Tg of polymers which favors antiplasticization of amorphous drugs. Whereas, at 
high molecular weight, the rise in Tg becomes insignificant as other factors such as 
viscosity come into play during the dissolution process. Viscosity of polymers increases 
with molecular weight which has significant effect on the dissolution properties. Once the 
polymers are selected, they are further screened based on the miscibility with the drug 
which is determined by film-casting method.  It involves mixing the drug and polymer in 
a common solvent and then applying the solution as a film.  Once the solvent is 
evaporated, the film is then analyzed under hot-stage microscopy to observe the presence 
of phase separation.  However, this approach is applicable only in processes such as spray 
drying where a solvent is used.  In the case of hot melt extrusion, the drug and polymer 
are directly in physical contact with each other without the presence of a solvent.  Their 
molecular mobility is less and depends on the processing temperature.  Therefore, results 
obtained from film-casting method are often overestimated compared to the actual results 
obtained from hot-melt extrusion.  This shows that there is a need to develop a robust 
methodology with the use of minimum material to successfully formulate solid 




theory and melting enthalpy approach as preformulation tools for the rational selection of 
polymers have been reported in the literature.  
 
1.4.1. Solubility Parameter Approach 
Solubility parameters are the numerical values that represent the dispersive, polar 
and hydrogen bonding forces in a molecule. They are calculated based on the functional 
groups present in the chemical structure of a molecule and they contribution to various 
intermolecular forces. These intermolecular forces were calculated using various group 
contribution methods, viz. Hoftyzer and Van Krevelen, Hoy, Small, Dunkel, Hayes, and 
Di Benedetto (21). Generally, drug polymer systems with similar solubility parameter 
values are predicted to be more miscible. Drug-polymer mixtures with the solubility 
parameter difference, Δδ < 7.0 MPa1/2 are found to be miscible whereas systems with Δδ 
> 10.0 MPa1/2 are likely to be immiscible (22). Estimation of drug-polymer miscibility 
based on the difference in the solubility parameter values is still one of the most applied 
approaches in the academia and pharmaceutical industry owing to its relative simplicity. 
Just et al. discussed about various attempts to improve group contribution parameters and 
to develop new values based on solids (23). Wlodarski et al. reported the use of the 
solubility parameters for the prediction of miscibility between itraconazole and two 
polymers, polyvinyl alcohol and copovidone (24). Pawar and co-workers used Hansen 
solubility parameters to predict the miscibility of efavirenz in polymers for the 
preparation of ASDs using HME (25). Although the solubility parameter can be useful 
for the fast screening of polymers, it often leads to the exclusion of good polymeric 




interpretations obtained using solubility parameter approach. Recently, Turpin et al. 
experimentally determined the miscibility of various model drugs and the results were 
compared with that of the results predicted using Hansen solubility parameters approach. 
(26). The study showed that the predicted results from the solubility parameters did not 
match the experimental data. The authors attributed this to the negligence of not 
considering the intermolecular interactions in the solubility parameter approach. To 
address these drawbacks, more complex methods were introduced to predict the drug-
polymer miscibility. One of these methods is the calculation of the Flory–Huggins 
interaction parameter (χd-p), usually through the application of the melting point 
depression (MPD) theory. 
 
1.4.2. Melting Point Depression Theory 
The most widely used method for the estimation of drug solubility in a polymer is 
by using the melting enthalpy of the crystalline drug in a drug-polymer system measured 
by DSC. This method is based on a simple principle that the fraction of drug dissolved in 
the polymer does not contribute to the melting endotherm. Therefore, by measuring the 
melting enthalpy of a series of drug concentrations in drug-polymer mixtures and 
extrapolating the plot to zero enthalpy, the solubility of a given drug in selected polymers 





1.4.3. Flory-Huggins Theory 
Flory-Huggins (F-H) theory is a well-known lattice-based theory which describes 
polymer-solvent miscibility on the basis of the Gibbs free energy change associated with 
the mixing of a polymer in a solvent (27). Recently, this theory was applied for assessing 
drug-polymer miscibility using the melting point depression method to obtain F-H 
interaction parameter, χd-p (22). A negative value of χd-p indicates stronger drug-polymer 
interaction than individual drug-drug or polymer-polymer interaction which predicts 
drug-polymer miscibility, whereas a positive value indicates that homonuclear 
interactions are preferred over heteronuclear interactions which may lead to phase 
separation (28).  This method is also used by the pharmaceutical industry and is probably 
the most popular approach, with research work published by many reputed 
pharmaceutical companies. Earlier, the assessment of acetaminophen and naproxen 
solubility in polymeric excipients, such as povidone and co-povidone, calculated with 
three models including F-H equation, was published by Lehmkemper and co-workers 
(29). The results were in line with the experimental solubility data. However, the F-H 
theory underestimated the effect of acetaminophen miscibility on stability. 
 
1.4.4. Thermodynamic Phase Diagrams 
Another common tool within the industry is the construction of phase diagrams 
which are usually based on the F-H theory. Phase diagrams depict the relationship 
between the free energy and drug loading. The use of phase diagrams have been 




temperature dependent, and an immiscible system can, therefore, become miscible if the 
temperature increases.  
 
1.5. Hot Melt Extrusion Process Optimization 
Once a suitable polymer is selected for the formulaton of ASDs, the next 
challenge is to determine the optimum formulation and process parameters. When 
choosing a commercial ASDs manufacturing process, there are two leading choices: 
spray drying or hot melt extrusion (HME). Although solvent-based processes are more 
common because they are applicable to a wide range of compounds, HME offers several 
advantages for thermally stable systems. It is solvent-free, continuous, high-throughput, 
easily scalable and inexpensive. Avoidance of thermal degradation and an absence of 
residual crystallinity are two critical quality attributes of hot melt extruded ASDs (36, 
37). To avoid thermal degradation of drug and/or polymer, lower processing temperatures 
are desirable, although accompanied by a risk of residual crystalline content if the 
crystals do not fully melt or dissolve during the process. Various studies have reported 
the HME processing at temperatures below the drug’s melting point utilizing melting 
point depression phenomenon (38, 39). Studies providing strategies to mitigate the 
corresponding risk of crystallinity have thus far been limited to equipment setup like 
screw configuration and drug particle size reduction (18). Physical instability and 
dissolution performance are affected by many parameters, such as drug loading, polymer 
type, miscibility, Tg and the inherent crystallization tendency of the drug and may be 
accelerated by the presence of seed crystals (36–39). Therefore it is considered critical to 




the FDA encouraging Quality by Design (QbD) practice for all the formulations, 
applying it in the case of ASDs seems challenging (40). This is due to various factors that 
effect the characteristics of ASDs. However, once the maximum drug loading was 
determined using preformulation studies, the process parameters can then be optimized 
using a suitable experimental design. Since fully amorphous systems are considered 
stable, it is significant to determine the maximum solubility of the drug in the polymeric 
carrier. The thermodynamic phase diagram has been conceptually proposed in the 
literature as a methodology for identifying the maximum solubility of the drug in the 
polymeric carrier as well as the processing temperature (36, 39). A typical 
thermodynamic phase diagram shown in Figure 2 consists of a solubility curve, a 









Figure 2: Typical thermodynamic phase diagram consisting of a solubility curve, a 






Most of the research in the field of HME is limited to a simple experimental 
design which fails to determine the interaction effect between the CMAs and the CQAs 
on the CMAs. Since HME is a complex process with various interaction effects, it is ideal 
to study the process using a design that better helps understand the effect of various 
CQAs and CPPs on the CMAs. However, it is challenging to perform enough 
experimental runs using HME, especially during initial phase of development due to 
limited availability of the drug. Therefore, material sparing techniques are necessary to 
speed up the formulation development process using HME. One such technique is DSC, a 
commonly used thermal analysis instrument. It is similar to HME in the case of heat 
conduction except the absence of mechanical stress. However, when the particle size of 
drug and polymer blend is reduced significantly, then the thermal events in the DSC and 
HME are comparable. Apart from that, DSC requires small quantity of material and the 
samples subjected to thermal analysis can be retrived and analyzed. Phase diagrams 
coupled with DoE could provide useful information regarding formulation and process 
optimization.  
 
1.6. Physical Stability of ASDs  
The amorphous drug–polymer dispersion is commonly characterized in terms of 
physical properties such as glass transition temperature (Tg), heat capacity, and 
miscibility (45, 46). Though it is widely regarded that an increase in Tg indicates the 
improvement of physical stability, there is no direct evidence disclosed to relate Tg to 
recrystallization activation energy, the critical parameter evaluating stability. Tg is not an 




measurement therefore are ambiguous. Some studies experimentally proved the 
surprising occurrence of nucleation below Tg indicating that Tg is not a reliable indicator 
of physical stability (41, 47). Recrystallization kinetics is a mathematical model which 
has a potential to estimate the physical stability of ASDs. The model is based on the 
approximation of the nucleation and crystal growth contributions which are inherently 
essential to an accurate prediction of the physical stability of ASDs. This approach was 
first introduced by Avrami and is the commonly used model to estimate the 
crystallization kinetics for decades (48, 49). However, the reliability and accuracy of this 
equation is compromised because of its critical oversimplifications, most notably that the 
nucleation rate is constant throughout the recrystallization process. Other models also 
have been developed based on solid state reaction kinetics (46–49), however, there has 
been little progress in their application to stability prediction of pharmaceutical solid 
dispersion. Most recently, a new kinetics model was developed by Yang et al. by 
correcting the critical oversimplification on nucleation rate in the Avrami equation (50). 
However, further studies need to be done to validate the applicability of the kinetic model 
to determine the shelf life of ASDs. 
 
1.7. Need to Restructure the Formulation Approach for ASDs 
A systematization of a rational approach to design solid dispersions is crucial for 
a successful, fast and low-cost development, which avoids promising formulations being 
prematurely eliminated from experimental studies. The most common approaches for 
screening excipients for HME formulations are based on solvent evaporation methods, 




evaporation methods are probably the most common in the industry setting, because of 
their simplicity and low cost. Some studies have been published, describing ways of 
automating and miniaturizing the screening of excipients in a high-throughput manner 
(51–53). However, DSC studies, HSM or melt-based methods have the advantage of 
applying heat which can be beneficial when the manufacturing process under study is 
HME. Auch and co-workers noticed discrepancies between a solvent-based screening 
method and experimental results for ASDs (54). Based on the literature a structured 
screening approach for the formulation of ASDs is presented in Figure 3. This 
methodology reflects the usual techniques, based on physicochemical principles and 
thermodynamic assessment of the drug and the polymer, with the aim of maximizing 
success rates and reducing risks. One of the main advantages is including the assessment 
of physical stability at the early stages during product development. This approach is 
divided into four stages. During the first stage, an in-depth evaluation of physicochemical 
properties of the drug and potential polymers is performed. Then, in the second stage, 
excipients are assessed through solubility parameters, melting point depression and 
Flory-Huggins interaction parameter. This preliminary evaluation can be complemented 
with experimental tests, such as DSC, where depression of the melting point evaluated 
and, eventually, the interaction parameter can be calculated. As an outcome, excipients 
with a high probability of miscibility and chemical interaction are taken to the third stage 
where the process optimization is done using the thermodynamic phase diagrams and a 
material sparing DSC method. The results from the DSC method is validated using 
samples prepared by vaccum compression molding (VCM) and HME. In the final stage, 





Figure 3: Proposed approach for early formulation development of ASDs by HME 
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2. Study Objectives 
The objective of the present study was to develop various material-sparing pre-
formulation tools for rapid formulation development of ASDs. To achieve this, various 
specific objectives were proposed which are as follows: 
1. To estimate the drug-polymer miscibility using solubility parameter approach and 
melting point depression method and to compare the results from both the 
approaches.  
2. To estimate the ideal drug loading and ideal processing temperature for HME using 
thermodynamic phase diagrams and Gibbs free energy plots. 
3. To develop a material-sparing method based on differential scanning calorimeter 
(DSC) to determine the design space for hot melt extrusion. 
4. To predict the physical stability of ASDs at various temperature and relative 





   
3. Materials and Methods 
3.1. Model Drug: Mefenamic acid 
Mefenamic acid was selected as a model drug based on its physicochemical 
properties.  It is a BCS class II drug with poor water-solubility and high permeability.  It 
has a pKa value of 4.2 making it a weakly acidic drug.  The rationale for the selection of 
mefenamic acid was its high melting point of 230 - 231 °C and its tendency to degrade 
upon melting.  This makes it a challenging drug to process using thermal techniques, i.e. 
hot-melt extrusion.  There are three polymorphic forms reported for mefenamic acid.  
Form III is the metastable form which transforms into form I at ambient conditions and 
into form II at elevated temperatures (55).  The saturated solubility of form II is more 
than form I, however, in the dissolution media, form II rapidly converts into form I.  
Therefore, the rate of conversion of form II into form I is the rate-limiting step in the 
dissolution of mefenamic acid. For the current study, mefenamic acid was purchased 
from Alfa Aesar (Haverhill, MA) 
 
3.2. Model Polymers 
Four model polymers, i.e. Eudragit® EPO (EPO), Kollidon® VA 64 (VA 64), 
Soluplus® (SLP) and Pluronic® F68 (F 68) were used as polymeric carrier materials.  
Eudragit® EPO was a kind gift from Evonik Corp. (Parsippany, NJ).  Soluplus®, 
Pluronic® F68 and Kollidon® VA64 were kind gifts from BASF Corp. (Florham Park, 
NJ).  These polymers were selected based on their glass transition temperature, Tg, 
solubilization capacity, hygroscopicity and toxicity profile.  These four polymers differ in 
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their chemical composition and ionic nature; F68 is a non-ionic, EPO is a cationic, and 
SLP and VA64 are amphoteric polymers in nature.  These polymers have similar 
solubility parameters to that of the drug MFA but differ in their chemical structure.  This 
helps to understand the role of solubility parameter in predicting the drug-polymer 
miscibility. 
 
3.3. Physicochemical Evaluation of Drug and Polymers 
3.3.1. Determination of Melting Temperature, Tm 
The melting temperature of drug and polymers were determined using a 
differential scanning calorimetry (DSC 6000, Perkin Elmer, USA) which was calibrated 
using indium standard prior to analysis.  During analysis, accurately weighed, 
approximately 10 mg of material was taken in an aluminum sample pan and thermal runs 
were conducted over a temperature ranges of 30° to 250 °C, depending on the melting 
point of the material reported in the literature. A heating rate of 5 °C/min and nitrogen 
gas flow rate of 50 mL/min were maintained.  The endpoint of the melting endotherm 
was taken as the melting point of the material. 
 
3.3.2. Determination of Degradation Temperature, Td 
 The degradation temperature of the drug and the polymers were determined using 
a thermogravimetric analyzer (PyrisTM 1 TGA, Perkin Elmer, USA).  The temperature 
calibration of the instrument was performed using nickel Cure point method before 
analysis.  Accurately weighed, approximately 10 mg of material was placed on a 
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platinum sample pan and thermal run was conducted over a temperature range of 30° to 
270 °C. A heating rate of 5 °C/min and nitrogen gas flow rate of 50 mL/min were 
maintained during analysis. The percent degradation was calculated from the difference 
in the initial and the final weight of the sample. 
   
3.3.3. Determination of Glass Transition Temperature, Tg 
The glass transition temperatures, Tg, of the drug and the polymers were 
determined using differential scanning calorimetry (DSC 6000, Perkin Elmer, USA).  
Accurately weighed, approximately 10 mg of material was placed and sealed in an 
aluminum sample pan.  The sample pan was equilibrated at 30°C for 1 min and heated to 
240°C at 5°C/min rate and modulation of 1°C/min.  The Tg of the drug and the polymers 
were determined using PyrisTM Manager software (Perkin Elmer, USA).   
 
3.3.4. Determination of True Density, ρ  
True density of the powder materials was determined using a gas pycnometer 
(AccuPyc® II 1340, Micromeritics Instruments Corp., Norcross, GA).  Prior to analysis, 
the pycnometer was calibrated with an iron sphere of known mass prior to each 
measurement.  During analysis, a known weight of powder sample was transferred into 
an aluminum sample container of 3.5 cm3 volume, and helium gas was passed through 
the sample from the reservoir.  The determinations were carried out at room temperature.  
The instrument automatically purges moisture and volatile materials from powder sample 
and repeats the analysis until successive measurements yield consistent results.  The 
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determination of sample density was repeated for up to 10 cycles.  The average reading of 
10 cycles was recorded as the true density of the material (56–59). 
 
3.4. Solubility Parameter Approach 
3.4.1. Calculation of Hildebrand Solubility Parameter, δ 
The calculation of the Hildebrand solubility parameter of a chemical is based on 
the cohesive energy density of the functional groups in its molecule.  Cohesive energy 
density is expressed as the cohesive energy, ∆Ev, of the molecules per unit volume, V.  
The Hildebrand solubility parameter is then calculated as the square root of the cohesive 
energy density of the molecule according to eq. (1).  The values of the ∆Ev and V of the 
functional groups were adapted from Fedors (60).   
δ = CED. =  (∆E V⁄ ).  (1) 
 
3.4.2. Calculation of Hansen Solubility Parameters, δt 
The Hansen solubility parameter is a modification of the Hildebrand method in 
which the cohesive energy is divided in three different forces, i.e. dispersion, polar and 
hydrogen bonding forces.  The Hansen solubility parameter is expressed as δt, and its 
value is calculated using the following equation (Eq. 2): 
δ = δ + δ + δ   (2) 
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Where δd, δp and δh are the dispersion forces, polar forces, and hydrogen bonding forces, 
respectively, in a molecule that are calculated using the following relationships: 
δ = ∑   ;    δ =
∑ 
  ;    δ = ∑    (3) 
 
The chemical structure of a molecule was divided in different functional groups 
and the values of Fdi, Fpi and Ehi were calculated according to the group contribution 
method by Van Krevelen-Hoftyzer for each functional groups in a molecule (61).  The 
value of molar volume, V was calculated according to Fedors (60). 
 
3.4.3. Construction of Bagley’s Plot 
Bagley et al. introduced the combined solubility parameter, δv, based on the 
thermodynamic considerations that dispersion forces, δd, and polar forces, δp, show 
similar effect, whereas the effect of δh is different (62).  The combined value of the 
solubility parameter, δv was calculated according to eq. (4):   
δ = δ + δ        (4) 
 
Bagley’s plot was constructed using the relationship between δv and δh which 
helps to project the three-dimensional solubility parameters into a two-dimensional plot. 
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3.4.4. Estimation of F-H interaction parameter, χ 
The Flory–Huggins interaction parameter between the drug and the polymers, χd-p 
was estimated using the solubility parameters of drug, δdrug and polymer, δpolymer 
according to the following equation: 
χ = V   

                                                      (5) 
 
Where χd-p represents the F-H interaction parameter between the drug and the polymer, V 
is the molar volume calculated according to the group contribution method from Fedors 
(60). R is the universal gas constant (8.314 J/mol.K); T is the temperature in Kelvin 
(293.1 K). 
 
3.5. Melting Point Depression Method 
3.5.1. Preparation of Drug-Polymer Physical Mixtures 
The drug-polymer physical mixtures were prepared by accurately weighing 
various ratios of drug and polymer and then gently mixing them together to form a 
homogenous mixture using a mortar and pestle.  Care was taken not to apply excessive 
mechanical stress on the mixture that could result in the amorphization of the drug. 
 
3.5.2. Determination of Melting Point of MFA 
The melting point of the mefenamic acid in drug-polymer mixtures was 
determined using a differential scanning calorimetry (DSC 6000, Perkin Elmer, USA).  
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Accurately weighed, approximately 10 mg of the drug-polymer mixture was taken in an 
aluminum sample pan and thermal runs were conducted over a temperature range of 30° 
to 250 °C at a heating rate of 5 °C/min under nitrogen gas flowing at the rate of 50 
ml/min.  The endpoint of the melting endotherm was taken as the melting point of the 
drug.  To ensure content uniformity, several samples were analyzed for each drug-
polymer ratio and only three samples (n=3) with the heat of fusion, ∆Hf, values of less 
than ±5% variation from the theoretical value were used for analysis. 
  
3.5.3. Estimation of Drug-Polymer Interaction Parameter 
The drug-polymer interaction parameter, χ, was estimated using the melting point 
depression using the following equation (Eq. 6): 

 −  = − ∆ lnϕ + 1 −  ϕ + χϕ    (6) 
 
Where Tm is the melting point of drug-polymer mixture (K); Tmo is the melting 
point of pure drug crystal (K); R is the real gas constant (8.314 J/mole K); ∆Hf is the heat 
of fusion of the drug (kJ/mol), ɸd is the volume fraction of the drug, ɸp is the volume 
fraction of the polymer, χ is the drug-polymer interaction parameter, and m is the degree 
of polymerization of the polymer which is the ratio of the volume of a polymer chain to 





                                                                       (7) 
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where the Mw(polymer) and Mw(drug) are the molecular weight of polymer and drug, 
respectively, and the ρpolymer and ρdrug are the density of polymer and drug, respectively. 
 
3.5.4. Establishing Relationship Between Interaction Parameter, χ and 
Temperatures 
The interaction parameter, χ between drug and polymer is temperature dependent. 
The value of χ estimated using the melting point depression method is clost to the melting 
temperature of the drug. To estimate the Gibbs free energy of mixing at various 
temperatures, the value of χ at various temperatures was estimated. This was done by 
determining the temperature dependence of the interaction parameter, χ using the 
following equation: 
 =  +   (8) 
 
Where A is the entropic contributions, and B is the enthalpic contributions for 
mixing.  These constants are used to theoretically calculate the value of χ at any specific 
temperature. 
 
3.6. Construction of Gibbs Free Energy Plots 
The Flory-Huggins theory relates the Gibbs free energy of mixing the drug-




   
∆G = RT ϕ ln ϕ +  ln ϕ + χϕϕ    (9) 
 
The value of the interaction parameter, χ at various temperatures was determined from 
eq. (8). These values were then used to estimate the Gibbs free energy of mixing (∆Gmix) 
at various temperatures.   
 
3.6.1. Validation of Gibbs Free Energy Plots 
The Gibbs free energy plots constructed using the Flory-Huggins theory were 
validated using a hot stage microscope (FP82HT, Mettler-Toledo, Greifensee, 
Switzerland) equipped with a Nikon Eclipse 50i microscope (Nikon Inc., Tokyo, Japan) 
with a 10x cross-polarized lens.  A 1:1 ratio of the drug and the polymer was dispersed in 
acetone and transferred onto a glass slide.  This step ensured that the drug and the 
polymer were mixed thoroughly.  After evaporation of the organic solvent, the samples 
were heated on the hot stage microscope from 30° to 230 °C at 10 °C/min rate and the 
changes in the drug crystal morphology as a function of temperature were recorded using 
a Nikon digital single-lens reflex camera attached to the microscope.  The onset 
temperature where the drug crystals were completely miscible in the polymeric matrix 
was recorded and compared with the results obtained from the Gibbs free energy plots. 
 
3.7. Construction of Thermodynamic Phase Diagrams 
A binary phase diagram depicts the maximum solubility and miscibility of an 
amorphous drug in the polymeric carrier as a function of temperature.  It consists of a 
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drug-polymer solubility curve, drug-polymer miscibility curve and the glass transition 
curve of the drug-polymer system. 
 
3.7.1. Estimation of Solubility Curve 
The solubility curve refers to the temperature at which the crystalline drug is in 
equilibrium with the dissolved or dispersed drug in the polymeric matrix. Marsac et al. 
proposed an approach for the estimation of the drug-polymer solubility that was based on 
the Flory-Huggins lattice theory (42).  According to the authors, the mole fraction 
solubility of a drug in the polymer is related to the activity coefficient of the drug and the 
interaction parameter between the drug and the polymer as expressed by the following 
equation (Eq. 10): 
ln γ x = ln ϕ + 1 −  ϕ + χ ϕ  (10) 
 
Where xdrug is the mole fraction of the drug dissolved or dispersed in the polymer, 
γdrug is the activity coefficient of the drug in the polymer, ϕdrug is the volume fraction of 
the drug, ϕpolymer is the volume fraction of the polymer, and m is the ratio of the volume 
of the polymer to the volume of the drug. 
Another approach to determine the temperature at which the crystalline drug is in 
equilibrium with the dissolved or dispersed drug in the polymeric matrix is using the 
following solid-liquid equilibrium (SLE) equation (Eq. 11): 
lnx = ∆ 1 −   − lnγ                                     (11) 
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Where xdrug is the mole fraction of the dissolved drug,  is the activity 
coefficient of the drug, T is the temperature of the two phases of the drug in equilibrium 
(K),  is the melting point of pure drug crystal (K), R is the real gas constant (8.314 
J/mol.K), and ∆Hf is the heat of fusion of the drug (kJ/mol).  
The value of activity coefficient, γdrug, of the drug can be calculated using the 
extended Hansen solubility model (Eq. 12): 
 
ln γ =  δ − δd
 + 0.25 δ − δp + δ − δh + ln  + 1 −     (12) 
 
Where V is the molar volume of the drug, δ is the Hansen solubility parameter,  
is the molar volume-weighted Hansen solubility parameter, and   is the mixture volume.  
The subscripts, d, p and h, stand for dispersion, polar and hydrogen-bonding forces, 
respectively.  
The values of mixture volume and molar volume-weighted Hansen solubility 
parameter can be calculated using the following equations: 
̅ = ∑                                                                   (13) 
 =                                                                         (14) 
 = ∑                                                                 (15) 
Where ϕ is the volume fraction, x is the mole fraction, M is the molecular weight, 
ρ is the density, and the subscript k denotes the different components of the mixture.  
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3.7.2. Estimation of Miscibility Curve 
The drug-polymer miscibility curve is also called as the spinodal decomposition 
curve that defines the boundary between the unstable zone and the metastable zone in the 
drug-polymer mixture.  It is plotted by equating the second derivative of the free energy 
to zero as expressed below (Eq. 16):  
T =    () 
                                                         (16) 
Where, ϕ is the volume fraction of the drug calculated using the true density of 
the drug and polymer, 1-ϕ is the volume fraction of the polymer, and m is the degree of 
polymerization of the polymer which is the ratio of the volume of a polymer chain to 
drug molecular volume.  The constants A and B are obtained by the melting point 
depression data obtained using eq. (8). 
 
3.7.3. Estimation of Glass Transition Curve 
The glass transition temperatures, Tg, of the drug and the polymers were 
determined using differential scanning calorimetry (DSC 6000, Perkin Elmer, USA).  
Accurately weighed, approximately 10 mg of material was placed and sealed in an 
aluminum sample pan.  The sample pan was equilibrated at 30°C for 1 min and heated to 
240°C at 5°C/min rate and modulation of 1°C/min.  The Tg of the drug and the polymers 
were determined using PyrisTM Manager software (Perkin Elmer, USA).  The glass 
transition temperature, Tg, of drug-polymer mixtures was predicted using the following 
Gordan-Taylor equation (Eq. 17) .  
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T = ,,()      K =

                                        (17) 
Where, w1, Tg and ρ are the weight fraction, the glass transition temperature, and 
true density of drug and polymer, respectively. 
 
3.8. Material Sparing DSC Method for Process Optimization of HME 
3.8.1. Analytical Techniques 
3.8.1.1. Differential Scanning Calorimeter 
A differential scanning calorimeter (DSC 6000, Perkin Elmer, USA) was used to 
determine the melting endotherm of crystalline drug, MFA. The instrument was 
calibrated using indium standard before analysis.  Accurately weighed, approximately 15 
mg of MFA was placed and sealed in an aluminum sample pan (50 µL) and heated over a 
temperature range of 30° to 250 °C at a heating rate of 1 °C/min to 10 °C/min under 
nitrogen gas flowing at the rate of 50 ml/min.  The final heating temperature and the 
heating rate were changed according to the experimental design.  The changes in the 
melting endotherm of MFA was recorded using PyrisTM Manager software (Perkin Elmer, 
USA). 
 
3.8.1.2. Thermo Gravimetric Analysis 
The thermal degradation of MFA was determined using a thermogravimetric 
analyzer (PyrisTM 1 TGA, Perkin Elmer, USA).  The temperature calibration of the 
instrument was performed using the nickel Curie point measurement method before 
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analysis.  Accurately weighed, approximately 10 mg of pure MFA was placed in a 
platinum sample pan and a thermal run was conducted over a temperature range of 30° to 
250 °C at various heating rates from 0.5 °C/min  to 15 °C/min under nitrogen gas flowing 
at the rate of 50 ml/min.  The heating rate was changed according to the experimental 
design. The percent weight loss was calculated from the difference in the initial and final 
weight of the sample using PyrisTM Manager software (Perkin Elmer, USA). 
 
3.8.1.3. High Performance Liquid Chromatography 
The amount of MFA in the samples was determined by carefully diluting them 
with mobile phase consisting of 46:40:14 ratio of acetonitrile, buffer solution (50 mM 
solution of monobasic ammonium phosphate adjusted with 3 M ammonium hydroxide to 
a pH of 5.0) and tetrahydrofuran. The diluted samples were then analyzed using a high-
performance liquid chromatography (HPLC) system (Agilent Corporation, USA) 
equipped with an autosampler (AS2055 Plus, intelligent sampler, JASCO Corp, Japan) 
and photodiode array detector (JASCO Corp., Japan). A Phenomenex Luna® reversed 
phase C18 column (150 × 4.6 mm; 5 μm particles) was used as a stationary phase. The 
flow rate was 1.5 mL/min. with an injection volume of 20 μL and the detection 
wavelength of 224 nm. 
 
3.8.1.4. X-Ray Powder Diffraction (pXRD) 
The presence of MFA crystals in the samples was determined by powder X-ray 
diffraction (pXRD) analysis using X-ray diffractometer (Shimadzu 6000, Shimadzu 
Corporation, Kyoto, Japan) which was calibrated using a quartz standard prior to 
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analysis. During analysis, the drug-polymer dispersions were placed uniformly on a glass 
sample holder to obtain a smooth and uniform surface. The samples were analyzed 
through a CuKa, monochromatic radiation source emitting X-ray radiation with generated 
voltage of 40 kV and current of 30 mA at room temperature. The diffraction patterns of 
samples were obtained by scanning over a continuous 2θ range of 10–50° at a rate of 2 
degree/min using a scan step size of 0.02 degree (63). 
 
3.8.2. Initial Screening to Set up Experimental Design 
Initial screening was performed to determine the study range for the experimental 
design. Film casting method was used to determine the maximum drug-polymer 
miscibility. Then, the minimum temperature at which the drug-polymer blends were 
completely miscible was determined using hot stage microscopy. Later, TGA analysis 
was performed at various heating rates to determine the temperature at which complete 
degradation of MFA occurs in the drug-polymer powder blends. 
 
3.8.2.1. Determination of Maximum Drug-Polymer Miscibility Using Film Casting 
Method 
The maximum miscibility of MFA in EPO was determined using film casting 
method. Various powder blends with MFA:EPO ratios from 1:1 to 1:4 was dissolved in 
enough quantity of acetone to form a clear solution. The resulting solutions were poured 
in aluminum pans and the solvent was evaporated at 50 °C. Once the solvent evaporated, 
the drug-polymer films were observed under a Nikon Eclipse 50i Microscope (Nikon 
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Inc., Tokyo, Japan) using 10x cross polarized lens to detect the presence of any 
crystalline MFA. The maximum drug loading at which no crystalline MFA was observed 
in the films was used for further analysis. 
 
3.8.2.2. Determination of Minimum Temperature of Miscibility (MTM) Using Hot 
Stage Microscopy 
The minimum temperature of miscibility (MTM) is the minimum temperature at 
which the drug crystal completely gets miscible in the polymeric carrier. To determine 
MTM, the powder blends of MFA and EPO corresponding to the maximum drug-
polymer miscibility (determined from film casting method) were prepared using a mortar 
and pestle. The powder blend was then heated on a hot stage (Mettler-Toledo FP82HT, 
Greifensee, Switzerland) equipped with a Nikon Eclipse 50i Microscope (Nikon Inc., 
Tokyo, Japan) using 10x cross polarized lens. A small amount (2-4 mg) of sample was 
placed on a glass slide with a cover glass and heated from 30 to 250 °C at 10 °C/min. 
Changes in the samples morphology were recorded as a function of temperature using a 
Nikon digital single-lens reflex camera attached to the microscope which were then 
analyzed to determine the minimum temperature at which the MFA crystals got 
completely miscible in the EPO matrix. 
 
3.8.2.3. Determination of the Relationship Between Heating Rate and Drug 
Degradation Using Thermogravimetric Analysis (TGA) 
The heating rate and the final heating temperature for the experimental design was 
determined using TGA analysis. The powder blends of MFA and EPO corresponding to 
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the maximum drug-polymer miscibility were heated in TGA. Briefly, 10 mg of drug-
polymer physical mixture was placed in a platinum sample pan and heated from 30° C to 
250° C at various heating rates from 0.5 °C/min to 15 °C/min. The percent weight change 
in the samples were analyzed using PyrisTM software V 8.0 (Perkin Elmer, USA). A 
relationship between the % weight loss and the TGA heating rate was established to 
determine the ideal heating rate for the experimental design. 
  
3.8.3. Box-Behnken Experimental Design  
In the present study, a Box-Behnken experimental design was used to study the 
effects of independent factors on the dependent factors (responses).  The experimental 
design consisted of three independent factors, viz. drug loading (X1), heating rate (X2), 
and processing temperature (X3).  These factors were studied at three levels, i.e. low, 
medium and high (-1, 0, +1). Out of the three factors, two factors were varied through the 
four possible combinations of low-high, while one factor was kept constant resulting in 
twelve experiments. The center point consisted of all the three factors at medium level 
and was peformed in triplicate to identify any manual errors during experimentation. In 
total, the Box-Behnken experimental design consisted of fifteen experimental runs 
(twelve blocks and three center point).  The levels of independent factors for the 
experimental design were determined from the initial screening experiments using film 
casting method, hot stage microscopy and TGA. 
As per the applied design, the relationship between controlled input variables with 
the responses was quantified and the true functional relationship was established. Usually 
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a second order polynomial equation is used in response surface methodology to describe 
the model which is as follows (Eq. 18) (64): 
 
Y = B0 + B1X1 + B2X2 + B3X3 + B11X21 + B22X22 + B33X23 + B12X1X2 + B23X2X3 + 
B13X1X3                                                                                                                    (Eq. 18) 
 
where Y is the level of predicted or measured response, B0 is the model constant or 
intercept, X1, X2 and X3 are independent variables, B1, B2 and B3 are linear coefficients, 
B12, B23 and B13 are interaction terms between independent variables or cross-product 
coefficients, and B11, B22 and B33 are quadratic coefficients. 
The dependent or response parameters selected for the study were residual 
crystallinity (Y1) and drug loss  degradation (Y2).  This design allowed estimation of the 
main factors and the interaction effects between the considerable independent parameters 
(40).  The relationship of between the independent parameters on the dependent 
parameters was demonstrated by response surface plots with regions of maxima (red) and 
minima (blue).  A commercial software (Design Expert, version 11, Stat-Ease Inc., 
Minneapolis, MN) was used to generate the Box-Behnken design matrix and to analyze 
the experimental data.  
 
3.8.4. Preparation of Drug-Polymer Dispersions Using DSC 
The drug-polymer physical mixtures were prepared according to the experimental 
design using a mortar and a pestle.  Around 20 mg of the physical mixture was heated 
using a differential scanning calorimeter (DSC 6000, Perkin Elmer, USA) in a 50 µL 
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aluminum sample pan.  The heating rates and final heating temperatures were maintained 
according to the experimental design.  In order to ensure the content uniformity in the 
physical mixtures, the heat of fusion, ∆Hf, of the melting endotherm of MFA was 
compared to that of the pure crystalline drug.  All the samples were stored in a desiccator 
for 24 hrs before characterization. A total of six samples were prepared at each 
experimental condition (n=6).  
 
3.8.5. Determination of Residual Crystallinity of Drug using DSC 
The residual crystallinity represents the percent of the total drug which remained 
in the crystalline form in a sample. It was calculated according to the heat of fusion 
values using following equation (Eq. 19): 
Residual crystallinity (%) =  ∆()∆() × 100                                       (19) 
The observed heat of fusion value, ΔHf (observed), was experimentally determined by 
heating the drug-polymer samples in a DSC at a rate of 5 °C/min from 30 °C to 230 °C. 
The ΔHf value was then computed as the area under the melting endotherm using Pyris 
software. The theoretical value of heat of fusion, ΔHf (Theoretical) (J/g) depends on the drug 
load and the heat of fusion of pure mefenamic acid, ΔHf (Pure drug), (134.0 J/g) was 
calculated using the following equation (Eq. 20): 
∆H () =   (%) × ∆H ( )                                (20) 
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3.8.6. Determination of Drug Degradation Using HPLC 
The drug degradation indicates the percent of the drug that degraded during 
heating cycle. It was determined by carefully diluting the drug-polymer dispersions from 
the DSC sample pans with the HPLC mobile phase. The diluted samples were then 
analyzed using HPLC and the area under the curve (AUC) values of the degradation peak 
and the drug peak were calculated using Agilent software (Agilent Corporation, USA). 
The percent degradation was then calculated using the following equation (Eq. 21): 
Drug degradation (%) = ()()() Χ 100                        (21) 
 
3.8.7. Statistical Analysis  
Multiple regression analysis of the experimental data was performed using Design 
Expert software, version 11 (Stat-Ease Inc., Minneapolis, MN). The experimental data 
were fitted in the second-order quadratic polynomial model along with added interaction 
terms. The model was analyzed based on the values of R2, adjusted R2 (Adj. R2), 
predicted R2 (Pred. R2), standard deviation (SD) and coefficient of variation (% CV). 
ANOVA was performed to determine if the independent parameters had significant effect 
on the response variables. The sum of squares (SS) and the mean square values of the 
model and the residuals were calculated and the significance of the independent 
parameters on the response variables was determined based on the F-value and P value. 
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The ability of the model to predict all the response variables was determined by 
calculating the values of lack of fit and the pure error.  
 
3.8.8. Selection of Optimum Experimental Conditions 
The selection of the optimum experimental conditions was carried out using both 
numerical and the graphical optimization. The target values of residual crystallinity and 
drug degradation were set at 15% and 5%, respectively to determine the optimum 
experimental conditions. The numerical optimization was performed to determine all the 
possible combinations of the independent parameters that result in the response variables 
within the target value. The optimum combination of the independent parameters was 
selected based on the desirability values.  Graphical optimization was also perfomed to 
determined the optimum experimental conditions to obtain the target values for residual 
crystallinity and drug degradation. An overlay plot was constructed  to determine design 
space of the independent parameters. Within the design space, any combination of the 
independent parameters results in a target residual crystallinity of less than 15% and a 
drug degradation of less than 5%.   
 
3.8.9. Validation of the Experimental Design 
The experimental design was validated using the linear correlation plots, the 
residual plots and the values of bias. The experimental design was validated to quantify 
the agreement between the predicted values and the experimentally determined values. 
Six different drug-polymer dispersions were prepared at various drug loadings, heating 
rate and processing temperature using DSC. The residual crystallinity and drug 
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degradation of the six drug-polymer dispersions were experimentally determined. The 
predicted values from the experimental design were compared with the experimentally 
determined values using linear correlation plots and residual plots. The mean percentage 
prediction error (percentage bias) was also calculated to determine the ability of the 
experimental model to predict the response variables. A lower value of percentage bias 
indicates that the model is not biased and can effectively predict the response variables. 
 
3.8.10. Preparation of Drug-Polymer Dispersions Using Hot Melt Extrusion 
Hot Melt extrusion was carried out using an 11-mm parallel twin screw melt 
extruder (Process 11, Thermo Fisher Scientific, Waltham, MA) comprising of 8 electric 
heating zones with an L/D ratio of 40. The feed zone (Zone 1) was maintained at room 
temperature and the subsequent zones (Zone 2, Zone 3, Zone 4, Zone 5, Zone 6 and Zone 
7) were setup at increasing temperature gradient as shown in Figure 2. Two high 
kneading elements (at zone 3 and between zone 6 and 7) and one low kneading element 
(between zone 4 and 5) were used. An extrusion element was used at the end of the barrel 
for the formation of extrudates (65). The screw speed was varied between 50 and 150 
rpm and the maximum temperature of the heating zones was set at 150 °C. The extrudates 







Figure 4: Screw design for HME used for processing MFA-EPO powder blends. K1, K2 





3.8.11. Preparation of Drug-Polymer Dispersions Using Vacuum Compression 
Molding 
A novel vacuum compression molding (VCM) tool was used to prepare the drug-
polymer dispersions and compare them with HME filaments. The VCM tool has a 
cylindrical design and consists of a main body, a base plate, a lid, a piston and separation 
foils. The lid and the base plate have O-ring seals that provide a gas-tight closure when 
connected to the main body  (66). Since the particle size difference between the drug and 
the polymer was high, the sample was prepared by dissolving the drug and the polymer in 
acetone prior to sample preparation. The solvent was evaporated until a molten mixture 
was observed. This molten mixture was then enclosed between two Teflon foils and 
loaded into the sample chamber. The tool was then placed on a pre-heated hot plate at 
150 °C. The heat was transferred across the base plate to the sample forming a 
homogeneous bubble-free specimen.  The samples were heated for a total of three 
minutes then the tool was subsequently cooled down and disassembled. The samples 
obtained were stored in an airtight container until further analysis. 
 
3.8.12. Characterization of Drug-Polymer Dispersions Prepared Using HME and 
VCM 
The drug-polymer dispersions prepared using HME and VCM were characterized 
to determine the total degradation and residual crystallinity of MFA according to the 
procedure mentioned earlier. Additionally, solid state characterization of the samples was 
performed using pXRD and DSC analysis to determine the crystalline state of MFA and 















3.9. Estimation of Physical Stability of ASDs Using Modified Avarami Equation 
3.9.1. Preparation of MFA Seed Crystals 
Seed crystals of MFA were prepared by dissolving 1 g MFA in 40 ml of acetone 
using a sonicating water bath (Elmasonic S 50R, USA). After the drug was completely 
dissolved in the acetonic solution, the sonicator was turned off and samples were left in 
the water bath overnight for slow cooling. The crystals were collected after all the solvent 
was evaporated and stored until further analysis. 
 
3.9.2. Preparation of Drug-Polymer Dispersions Using Heat Molding 
The ASDs of MFA-EPO were prepared using a heat molding system developed 
in-house. The drug and the polymer were size reduced in a mortar and pestle and then 
sieved using #270 sieve (53 µm opening). Approximately, 2 g of MFA-EPO mixture 
(4:6) was prepared by properly weighing on a weighing balance and then transferred on 
to a hot plate. A 2 cm diameter cylindrical mold was placed on the hot plate and the drug-
polymer mixture was placed in between two PTFE films. The drug-polymer mixture was 
evenly distributed inside the mold using a 2 cm die and the mixture was heated until 160 
°C for 15 min. The samples were carefully transferred into a cooling chamber and flash 
cooled using nitrogen gas. After the samples were cooled, they were milled in a 
cryogenic mill to obtain a fine powder. The samples were taken out and stored at room 




3.9.3. Modified Avarami Equation to Estimate the Physical Stability of ASDs 
The modified Avarami equation contains of two essential assumptions – (i) 
nucleation rate is proportional to amorphous fraction, and (ii) crystal size grows linearly 
with respect to crystallization time from t = 0 to the final crystal size. These assumptions 
can be mathematically expressed as: 
() = (1 − ())                                                     (22) 
where Jo is the initial nucleation rate and 1- α(t) is a function of crystallization time. 
 =                                                                       (23) 
where r is the radius for spherical crystal, and β is crystal growth rate. During the time 
interval τ to dτ, the number of nuclei generated is: 
 = 1 − ()                                                   (24) 
Since each nuclei will grow into a sphere of radius β(t-τ ), the increased volume due to 
nuclei appearing in the time interval will be: 
() =  ( − )1 − ()                            (25) 
where V(t) is the volume transformed into the crystalline state. It is also related to the 
relative crystallinity by the Avrami phase transition theory: 
1 − () = (())                                                      (26) 
The derivative of the above equation provides an expression for the created crystalline 




() = () ()                                                   (27) 
A relationship between (t) and  is established by solving Eqs. (25) and (27): 

() () =  ( − )                                          (28) 
Integration of eq. (28) gives the final model equation for spherical crystal growth: 
α(t) = 1 −                                                          (29) 
where k is crystallization rate constant, expressed as the production of nucleation rate 
constant, Jo, and crystal growth rate constant, β. 
 =                                                              (30) 
A more general form for relative crystallinity can be presented as: 
α(t) = 1 −                                                          (31) 
Where the exponent, n, describes the dimensionality of crystal growth, and equals 
2, 3 and 4 for rod, plate, and spherical geometry, respectively for homogeneous 
nucleation. A general form of k can be expressed in terms of activation energy, ΔEA, and 
T according to the Arrhenius equation (Eq. 32). (Yoshioka et al., 1994): 
 = exp − ∆                                                     (32) 
Where ko is the pre-exponential factor, R is the universal gas constant, and T is the 
absolute temperature in the unit of kelvin. By correlating the crystallization rate constant, 
k, as a function of relative humidity and temperature, the optimum stability conditions of 




3.9.4. Preparation of Stability Chambers Using Saturated Salt Solutions 
The drug-polymer samples were stored at various relative humidity (% RH) and 
temperatures as shown in Table 3. The ASD samples were stored in glass humidity 
chambers with different saturated salt solutions. The humidity chambers were kept in 
laboratory oven (VWR International, USA) at different temperatures. The relative 
humidity and temperature of the humidity chambers were monitored using 
humidity/temperature monitor (Sper Scientific, China). 
3.9.5. Determination of Relative Degree of Crystallinity  
The ASD samples stored at various storage conditions were taken out periodically 
at predetermined time points, and the extent of recrystallization was determined using a 
DSC by heating the samples from 30 °C to 240 °C at 20 °C/min.  The relative degree of 
crystallinity, α(t), was calculated using the following equation (Eq. 33): 
α(t) = ∆()∆                                                                   (33) 
Where ∆() is the heat of fusion of the drug at a time, t, and ∆ is the heat of fusion of 
the drug after complete recrystallization. 
3.9.6. Estimation of Recrystallization Rate Constant, k 
The recrystallization rate constant, k, was estimated using the mathematical model 
according to eq. (33). A non-linear regression analysis was performed between the 
relative degree of crystallinity, α(t), with respect to time, t, using Origin Pro V.8.5 





Table 3: Various storage conditions used to study the recrystallization kinetics of drug 




   
Temperature ( 
°C) 
  Relative 
Humidity (%) 
To study the effect of 
temperature on the 
crystallization rate 
constant, k 
Sodium Chloride 25 75 
Sodium Chloride 40 75 
Sodium Chloride 60 75 
Sodium Chloride 80 75 
Sodium Chloride 100 75 
To study the effect of 
relative humidity on the 
crystallization rate 
constant, k 







Potassium Iodide 60 57 




4. Results and Discussion 
4.1. Thermal analysis of Mefenamic acid (MFA) and Polymers 
The physicochemical evaluation of the drug (MFA) and the thermoplastic 
polymers was conducted using DSC and TGA. The plots of thermogravimetric analysis 
of MFA is shown in Figure 6a.  The weight loss of MFA when heated between 180 °C 
and 230 °C was found to be 4.3%.  This indicates that mefenamic acid undergoes 
degradation before its melting point.  Beyond 230 °C, rapid degradation of MFA was 
observed until 270 °C with a total weight loss of 68.5%.  This was possibly due to 
increased molecular mobility of MFA after melting thereby exposing the carboxylic acid 
group (-COOH) of the molecule.  The results obtained by thermo-gravimetric analysis are 
in accordance with the thermal decomposition of MFA observed by rapid ESI-MS 
method as reported by Zhou and Gilpin (67).  The authors reported that when MFA was 
dissolved in a mobile phase consisting of methanol-water (80:20 v/v) and subjected to 
thermal degradation between 130 °C and 230 °C, MFA was converted to MFA-H+, which 
is completely converted to the final decomposition fragment with an m/z value of 224 at 
a temperature of 230 °C.  In the present study, only 4.3% degradation was observed at 
230 °C.  This was possibly due to the nature of the sample where MFA was present in 
solid form rather than molecularly dispersed form.  Also, the time scale of thermo-
gravimetric analysis was a magnitude of minutes in the case of rapid ESI-MS, it was 
hours which provides sufficient time and energy for degradation of MFA. 
The DSC thermogram of MFA showed two endotherms, a shallow endotherm at 




sharp endotherm at 231 °C indicating melting of form II (Fig. 6b).  The melting of MFA 
is followed by its degradation due to decarboxylation.  The cooling cycle showed an 
exothermic peak with a low intensity at 110 °C which indicates that mefenamic acid is 
not a glass former and undergoes recrystallization during cooling.  An endothermic peak 
was observed in the second heating cycle which indicated the melting of the residual 
crystalline MFA from the cooling cycle.  The results from the thermal analysis 
demonstrated the thermal degradation and recrystallization potential of MFA making it a 
challenging molecule to process using hot-melt extrusion. 
The DSC scans of the polymers is shown in Figure 7. The glass transition 
temperature, Tg of the polymers was found to be in between the range of 55 to 101 °C. 









Figure 6: (a) TGA thermogram showing degradation of MFA in the temperature range 
between 180 °C and 270 °C, (b) DSC thermogram showing recrystallization of 












4.2. Calculation of Solubility Parameters 
4.2.1. Hildebrand and Hansen Solubility Parameters 
The values of the solubility parameters of MFA and the polymers estimated 
according to Hildebrand and Hansen method have been summarized in Table 4.  It was 
observed that the values of the solubility parameter of the polymers were very similar 
according to both Hildebrand and Hansen method.  However, the value of Hildebrand 
solubility parameter for MFA was found to be 20.40 MPa0.5 whereas that of Hansen 
solubility parameter was 23.59 MPa0.5. The difference between the two values was 
mainly due to the fundamental difference between Hildebrand and Hansen methods. In 
the Hildebrand method, the solubility parameter was calculated using only the cohesive 
energy density of the molecules whereas in Hansen method, the solubility parameter is 
dependent on the dispersive, polar and hydrogen bonding forces in a molecule.  
Irrespective of the method used, both Hildebrand and Hansen approach demonstrated that 
the difference in the solubility parameter between MFA and the polymers was < 7 MPa0.5 
that indicates a good miscibility between MFA and the polymers according to 
Greenhalgh (68).  Upon comparing the values of Hildebrand solubility parameters of 
MFA and the polymers, it can be inferred that MFA would have good miscibility with 
F68 due to a very small difference in the values of solubility parameters of the two (∆δ = 
0.04 MPa0.5).  Based on the solubility parameters of MFA and the polymers, it can be 
predicted that the order of miscibility of MFA in the four polymers according to the 
Hildebrand solubility parameter will be F68> EPO> SLP> VA64.  The values of the 
Hansen solubility parameter of the drug and the polymers also indicated that MFA would 




polymers being F68> SLP> VA64> EPO. To further understand the effect of solubility 





Table 4: Physicochemical properties and the calculated values of Hildebrand and Hansen 
solubility parameters of mefenamic acid (MFA) and Eudragit® EPO, Soluplus®,  



























MFA 4390 220720 13100 185.8 20.40 23.59 - - 
EPO 6010 2270 26000 350.2 20.17 19.47 0.0040 1.268 
SLP 4300 2690 56000 238.7 25.16 20.22 1.6970 0.849 
F68 2470 1800 46000 140.6 26.19 19.81 2.5085 1.071 




4.2.2. Construction of Bagley Plot 
The Bagley plot (Fig. 8) represents the three-dimensional solubility parameters 
determined using the three intermolecular forces (δd, δp , δh) in a two-dimensional plot 
(δv, δh) according to Bagley et al. (62). It was observed from the plot that MFA was close 
to EPO indicating good miscibility between MFA and EPO.  The distance between the 
drug and the polymer in the Bagley plot referred as Ra,v was calculated according to the 
following equation: 
, =  ( − ) + ( − )  (34) 
 According to Bagley et al., when the Ra,v value is <5.6 MPa
0.5, the drug and the 
polymer are miscible and when the Ra,v values is > 5.6 MPa
0.5, it indicates that the drug 
and the polymer are immiscible.  The Ra,v values were found to be 4.70 MPa
0.5, 1.73 
MPa0.5, 1.09 MPa0.5 and 1.08 MPa0.5 for MFA-EPO, MFA-SLP, MFA-VA64 and MFA-
F68, respectively.  Based on the Ra,v values, one can therefore conclude that MFA will be 
miscible in all the four ploymers. By comparing the values of Hildebrand solubility 
parameters and Hansen solubility parameters, and the Bagley plots, it can be seen that 
three methods predicted the miscibility of MFA differently in different polymers.  The 
Hildebrand approach predicted that MFA would have a good miscibility with EPO 
whereas the Hansen approach predicted that MFA would have good miscibility with 
VA64. The Bagley plots predicted that MFA would have a good miscibility with SLP.  
This discrepancy between the three approaches was possibly due to the fundamental 




predict the miscibility.  While the Hildebrand approach is based on the calculation of the 
cohesive energy density of the molecules, the Hansen approach is based on calculating 
different intermolecular forces in a molecule.  However, it should be noted that all the 
theoretical approaches indicated that the drug MFA will be miscible in all the four 
polymers. This shows that the assumption that a difference in the solubility parameter, 
∆δ, of < 7 MPa0.5 between the drug and the polymer does not always indicate miscibility.  
However, since these are theoretical estimates, these results were, therefore, validated 







Figure 8: Bagley plots of hydrogen bonding forces as a function of combined solubility 
parameter for mefenamic acid, Eudragit® EPO, Soluplus®, Kollidon® VA64, 













































4.3. Melting Point Depression of Mefenamic acid in Various Polymers 
 The plots of melting point depression of MFA as a function of polymer fraction in 
various polymers are shown in Figure 9 and the numerical data are given in Table 5.  
From Figure 9, it can be seen that the melting point of MFA decreased rapidly in the 
presence of SLP, followed by EPO, VA64, and F68.  The melting endotherm of MFA 
was not observed after 60%, 75%, 75% and 50% concentration of MFA-EPO, MFA-SLP, 
MFA-VA64 and MFA-F68, respectively.  This indicates concentration-dependent 
miscibility of MFA with the four polymers.  It was interesting to observe that the melting 
temperature of MFA changed with the polymer.  This was possibly due to difference in 
the thermal conductivity and melt viscosity of the polymers.  The absence of melting 
endotherm in the case of MFA-SLP and MFA-VA64 below 75% MFA may be due to the 
presence of MFA in microcrystalline form at the melting temperature.  In that case, the 
value of heat of fusion, ∆Hf, of these crystals was too low to be detected by DSC.  
However, based on the results from melting point depression, it can be concluded that 
MFA had concentration-dependent miscibility with both EPO and SLP.  To further 
understand the miscibility of MFA in the four polymers, mathematical models were used 
to estimate the value of drug-polymer interaction parameter, χ, and the mole fraction of 





Table 5: Depression in the melting point of mefenamic acid (MFA) with increasing 




Melting Temperature of Mefenamic acid (ºC) 
Eudragit® EPO Soluplus®  Kollidon® VA64  Pluronic® F68 
95 230.30±0.46 231.10±0.22 230.68±0.72 230.15±0.95 
90 228.64±0.26 229.50±0.21 229.64±0.34 229.95±0.68 
85 226.81±0.32 227.11±0.16 228.21±0.51 229.64±1.22 
80 224.71±0.85 223.41±0.58 227.28±0.56 229.13±0.94 
75 221.98±0.65 218.93±0.42 225.04±0.87 228.57±0.86 
70 218.20±0.97 - - 227.64±0.75 
60 208.86±1.32 - - 225.40±1.06 
55 - - - 223.87±0.65 
50 - - - 221.85±1.33 
 
   * The data are presented as mean ± standard deviation (n=3). 
  **The blank spaces in columns indicate that no melting endotherm was observed for 







Figure 9: Plot showing depression in the melting point of MFA as a function of polymer 
fraction (by volume) in the drug-polymer mixture.  The error bars represent 


































4.4. Estimation of Drug-Polymer Interaction Parameter from Melting Point 
Depression Data 
 The melting point depression of MFA resulting because of polymers may be used 
to estimate the value of drug-polymer interaction parameter, χ.  In the present 
investigations, the relationship between an increase in the polymer concentration in the 
drug-polymer mixture resulting in a decrease in the melting point of MFA was plotted 
according to eq. (6) (Fig. 10).  A linear relationship was observed for all the drug-
polymer mixtures which allowed for the estimation of the value of interaction parameter, 
χ, from the slope of the fitted line.  A negative value of the interaction parameter was 
observed for MFA-EPO, MFA-SLP and MFA-VA64 mixtures indicating good drug-
polymer miscibility. A positive value of the interaction parameter was observed in MFA-
F68 mixtures indicating that they were immiscible or poorly miscible.  Also, a closer look 
at the MFA-EPO plot shows a lack of linearity at higher concentration of MFA (Fig. 10). 
This suggests a dependence of the interaction parameter, χ, on the composition of the 
MFA-EPO mixture. This observation is in agreement with the previously reported studies 
involving mixtures of carbamazepine and Soluplus® (69) and nifedipine and poly(vinyl 
pyrrolidone) (70). Also, the value of interaction parameter, χ, for MFA-SLP mixture was 
found to be -3.05 which according to Marsac et al. indicates adhesive enthalpic 
interaction of favorable miscibility between MFA and SLP (42). 
 The temperature dependence of the interaction parameter exhibits first-order 
kinetic relationship according to eq. (8).  The plot of values of interaction parameter, χ, as 
a function of 1/T for various drug-polymer mixtures is shown in Figure 11.  In the case of 




across the experimental composition of 80% to 50% MFA in the composition with an R2 
value of 0.7747. In the case of MFA-EPO system, a linear relationship was observed 
from 80% to 60% MFA composition with an R2 value of 0.9703. For the MFA-SLP 
system, a linear relationship was observed from 85% MFA to 75% MFA with an R2 value 
of 0.9896.  Similarly, for the MFA-VA64 system, a linear relationship was observed from 
85% to 75% MFA with an R2-value of 0.9859.  A non-linear relationship was observed at 
lower values of 1/T that corresponds to higher temperature and high drug loading.  This is 
in line with previously reported studies where non-linearity was observed at high drug 
loading in the case of indomethacin-PVP-VA64 system (70) and felodipine-Soluplus® 
and felodipine-HPMCAS systems (28).  The regression equation from the linear region in 
Figure 6 was used to estimate the entropic (A) and enthalpic (B) constants of 
corresponding drug-polymer mixtures.  These values were used to obtain the value of 
interaction parameter at various temperatures which were subsequently used to estimate 










































































y = 6.7635x - 15.603
R² = 0.9703
y = 24.338x - 50.262
R² = 0.9859
y = 7.4529x - 18.12
R² = 0.9896
































4.5. Estimation of Gibbs Free Energy of Mixing 
The Gibbs free energy of mixing, ∆Gmix indicates the energy change (enthalpy) 
and the disorderliness (entropy) in a drug-polymer mixture. A negative value of ∆Gmix 
indicates miscibility and a positive value indicates immiscibility between drug and the 
polymer.  Since the drug-polymer mixtures are non-ideal systems, the total Gibbs free 
energy of mixing is expressed as ∆Gmix/RT. Estimation of ∆Gmix/RT at various 
temperatures helps to determine the critical processing temperature required for complete 
mixing of the drug and the polymer.  The plot of Gibbs free energy of mixing, ∆Gmix/RT, 
as a function of volume fraction of MFA in the four polymers at various temperatures is 
shown in Figure 12.  It was observed that the interaction parameter significantly affected 
the Gibbs free energy of mixing of MFA in all the four polymers.  At room temperature 
(25 °C), the Gibbs free energy of mixing, ∆Gmix/RT, was positive for all the drug-
polymer mixtures, indicating immiscibility.  As the temperature increased, the values of 
Gibbs free energy of mixing, ∆Gmix/RT, decreased and eventually became negative, 
indicating miscibility.  In the case of the MFA-VA64 system, the effect of temperature on 
the Gibbs free energy of mixing was found to be significant compared to other drug-
polymer mixtures. 
The temperature at which the Gibbs free energy becomes negative depended on 
the polymer.  In the case of MFA-F68 and MFA-VA64 system, the Gibbs free energy 
was negative at 200 °C, and in the case of MFA-SLP and MFA-EPO, it was at 140 °C.  
These temperatures indicate the formation of a homogeneous mixture that was 
thermodynamically stable at all drug-polymer compositions.  The information from these 







Figure 12: Plots of the values of Gibbs free energy, ∆Gmix/RT, versus volume fraction of 
the drug, ϕdrug, for drug-polymer mixtures at 25 °C, 100 °C, 140 °C, 200 °C, 





4.6. Validation of Gibbs Free Energy Plots 
The polarized light microscopy images of MFA in various polymers at different 
temperatures are shown in Figure 13. The morphology of the MFA crystals at 50 °C was 
distinct in different polymers. While sharp needle like crystals were observed in case of 
MFA-VA64 (Fig. 13(j)), small rod like crystals were observed in case of MFA-F68 (Fig. 
13(d)). In the case of MFA-EPO and MFA-SLP, the drug crystals were present as small 
aggregates along with the polymer (Figs. 13a and 13g). The morphology of the crystals at 
room temperature itself indicated that MFA had good miscibility with EPO and SLP. The 
onset temperature is the point where the MFA crystals just start to melt and dissolve in 
the polymeric matrix. In case of MFA-EPO system, the onset temperature was observed 
at around 130 °C (Fig. 13)) and almost all the MFA crystals were dissolved in EPO by 
150 °C (Fig. 13c). These results were in accordance with the Gibbs free energy plots 
which predicted that the upper solution critical temperature (USCT) of MFA in EPO in 
between 100 - 140 °C. Similarly, the USCT of MFA-F68 and MFA-VA64 were found to 
be in between 180 °C - 200 °C (Figs. 13f and 13l)) and for MFA-SLP it was found to be 
in between 130 °C - 150 °C (Fig. 13i). These results were in accordance with the 
predicted values of the Gibbs energy plots (Fig. 12) which establishes the validity 
between the theoretically predicted and the experimentally observed values. These values 






Figure 13: Polarized light micrographs of 1:1 ratio of MFA-EPO at 50 °C (a), 130 °C (b), 
and 150 °C (C); MFA-F68 at 50 °C (d), 180 °C (e), and 200 °C (f); MFA-SLP 
at 50 °C (g), 130 °C (h), and 150 °C (i); and MFA-VA64 at 50 °C (j), 180 °C 





4.7. Determination of Solubility, Miscibility and Glass Transition Curves 
A typical thermodynamic phase diagram consists of a solubility curve, a 
miscibility curve and a glass transition curve. Initially, the activity coefficient, γdrug of 
MFA in the polymers was estimated using Hansen solubility parameter. Later, these 
values were used to estimate the value of xdrug which is mole fraction of molecularly 
dispersed drug in the polymer using solid-liquid equilibrium (SLE) equation. This 
information was used to construct the solubility curve according to F-H lattice theory. 
 
4.7.1. Estimation of Activity Coefficient of Mefenamic acid in Various Polymers 
 The value of activity coefficient of MFA in various polymers was calculated 
using to eq. (12) for various drug-polymer mixtures with MFA concentration in the 
mixture ranging from 2.5% w/w to 50% w/w.  Figure 14 shows plots of temperature 
dependence of the values of activity coefficient, γdrug, for various drug-polymer mixtures.  
The drug-polymer miscibility is expected to increase with an increase in the temperature 
due to an increase in the mobility of the drug and the polymeric molecules.  The dotted 
lines in the plots shown in Figure 14 indicate the ideal mixing in which case the value of 
activity coefficient is 1 (i.e., lnγdrug = 0).  From the plots, it can be observed that the 
activity coefficient of MFA was dependent on the ratio of MFA in the drug-polymer 
mixture for all the four drug-polymer mixtures.  An increase in the concentration of MFA 
in the mixture resulted in an increase in the value of activity coefficient of the drug, γdrug.  
However, for all the drug-polymer mixtures, the value of activity coefficient was found to 
be <1 (i.e., lnγdrug < 0) for up to 25% w/w MFA at room temperature (25 °C).  Frank et al. 




γdrug <1 (71).  According to this, MFA should form a solid solution with all the four 
polymers at room temperature at a drug loading of 25% w/w and lower.  However, in the 
present study, this was not the case as the results of the melting point depression showed 
that MFA was immiscible in all the four polymers at a drug loading of 25% at room 
temperature. This clearly shows that the value of the activity coefficient of MFA in the 
four polymers was underestimated due to its mathematical form. In eq. (12), it can be 
clearly seen that the difference in the magnitude of dispersion, hydrogen bonding and 
polar forces between the drug and the polymer determine the value of the activity 
coefficient. However, it does not consider the fact that even when the difference in the 
magnitude is lower for one of the three forces, the drug and polymer will be miscible in 
each other. While estimation of the value of activity coefficient using eq. (12) include 
contribution of all types of intermolecular forces equally which resulted in the values of 
activity coefficient of MFA obtained with the four polymers to be relatively low that 







Figure 14:Plots demonstrating the change in the value of activity coefficient, γdrug, of 
MFA as a function of temperature.  The figure legends indicate % weight 





4.7.2. Estimation of Mole Fraction Solubility of Mefenamic acid in Various 
Polymers 
The mole fraction of MFA dispersed in the four polymers studied as a function of 
temperature was estimated according to eq. (10) and the results are plotted in Figure 15.  
The horizontal dotted line in the plots indicates the ideal case of complete dissolution of 
MFA in the polymers.  It can be observed from the plots that the mole fraction solubility 
of MFA in all the polymers was composition-dependent at room temperature whereas it 
was found to be independent of drug composition (up to 5% w/w) at higher temperatures.  
In the case of the MFA-SLP mixture, the complete dissolution of MFA in SLP was 
observed at ~125 °C.  In the case of MFA-EPO, it was observed at ~150 °C, for MFA-
F68 it was observed at ~200 °C, and for MFA-VA64 it was observed at ~205 °C.  The 
temperature at which the mole fraction of MFA dispersed in the polymers was less than 0 
(xdrug = 0) is termed as the critical temperature (Tc).  At this critical temperature, MFA 
starts to disperse in the polymer.  For MFA-SLP and MFA-EPO system, the critical 
temperature was found to be dependent on the composition of MFA in the mixture 
whereas in the case of MFA-F68 and MFA-VA64, it was found to be independent of the 
composition.  The critical temperature was found to be in between 85-95 °C for MFA-
SLP, 90-110 °C for MFA-EPO, 175-185 °C for MFA-F68, and 195-200 °C for MFA-








Figure 15:  Plots demonstrating the change in the mole fraction of dispersed MFA as a 
function of temperature estimated using Flory-Huggins theory.  The figure 







Another approach to estimate the mole fraction of MFA dispersed in the polymeric 
carrier is by use of solid-liquid equilibrium (SLE) equation. According to eq. (11), the 
mole fraction of MFA dispersed in the polymers was estimated using the values of the 
activity coefficient of MFA in the polymers obtained using eq. (12). The mole fraction, 
xdrug, of MFA dispersed in the polymers as a function of temperature is presented in 
Figure 16.  The results demonstrated that the mole fraction of MFA dispersed in the 
polymer increased as a function of temperature, however, an increase in the concentration 
of MFA in drug-polymer mixture led to the decrease in the miscibility of MFA in the 
polymer.  At lower temperatures (i.e., < 75 °C), the drug-polymer miscibility was found 
to be independent of drug-polymer composition, however, at higher temperatures, the 
miscibility was composition-dependent and decreased with an increase in the 
concentration of MFA in the mixture.  Ideal mixing was observed for up to 5% w/w 
concentration of MFA in the mixture which indicates complete molecular dispersion of 
MFA in all the four polymers.  Unlike the results obtained from Flory-Huggins theory, no 
negative values were obtained for xdrug using the solid-liquid equilibrium (SLE) equation.  
A closer look at the plots in Figure 16 shows that the mole fraction, xdrug, of MFA 
dispersed in the polymers is both dependent on temperature and drug loading, making it 
difficult to determine the solubility curve using the theoretical approach. Therefore, a 
simple and novel approach was used in the current study to determine the solubility of 







Figure 16: Plots demonstrating the change in the mole fraction of dispersed MFA as a 
function of temperature estimated using the solid-liquid equilibrium (SLE) 
equation.  The figure legends indicate % weight fraction of the drug (MFA) in 






4.7.3. Determination of Solubility Curve Using Melting Point Depression Data 
A melting point is the temperature at which the drug crystal overcomes the lattice 
energy and gets dissolved in the polymeric matrix. While it is easy to determine the 
melting point of MFA in drug-polymer blends with higher drug loading, it is challenging 
to estimate the melting point of MFA at lower drug loading. However, it was indirectly 
estimated using the melting point depression data. A relationship was established 
between the weight fraction of the drug and melting temperature using a polynomial 
equation. This relationship was used to estimate the melting temperature of the drug at 
lower drug loadings. The plots between the melting temperature and weight fraction of 
MFA in various polymers is shown in Figure 17. In all the drug-polymer blends, the 
melting point data fitted well with the weight fraction of MFA using a polynomial 
equation with R2 values of > 0.99. Based on the polynomial equation, the melting point 
of MFA at various drug loadings was determined and this data was used to estimate the 
solubility curve.  
 
4.7.4. Determination of Miscibility Curve and Glass Transition Curve 
A miscibility curve represents the boundary above which the drug is present at a 
supersaturated state and undergoes spontaneous phase separation. Unlike solubility curve, 
there are no reported experimental techniques in the literature to estimate the miscibility 
of drug and polymer with respect to drug loading and temperature. Therefore, in the 
current study, miscibility of MFA in the polymers was estimated according to eq. (16) 




data. The glass transition curve was plotted according to the Gordan Taylor equation 







Figure 17: The plots showing a polynomial relationship between the melting temperature 





4.7.5. Construction of Thermodynamic Phase Diagrams 
The thermodynamic phase diagrams of MFA in the four polymers are shown in 
Figure 18. The solubility curve represents the boundary where the fraction of MFA is 
dissolved into the polymeric matrix. A miscibility curve represents the boundary above 
which the drug is present at a supersaturated state and undergoes spontaneous phase 
separation. The glass transition curve, Tg predicted using the Gordan-Taylor equation 
indicates the molecular mobility of the drug and the polymer within the amorphous solid 
dispersion system. In the region above the Tg curve, phase separation is 
thermodynamically favored due to increase in the mobility of the polymeric strands, 
which reduces the activation energy for nucleation and subsequently, crystal growth. 
Below the Tg curve, the system remains stable due to the kinetic hinderance caused by the 
polymeric strands. The region between the miscibility curve and the solubility curve 
indicate the metastable zone where the drug-polymer system remains stable at 
temperatures below Tg but can undergo phase separation at temperatures above Tg. The 
point where the miscibility curve intercepts the glass transition curve is called Berghmans 
point (72).  It theoretically defines the maximum drug concentration that will be stable 
without undergoing phase separation until the temperature reaches the Tg of the drug-
polymer mixture. By comparing the thermodynamic phase diagrams of MFA in the four 
polymers, the miscibility of MFA is higher in case of EPO, followed by SLP, F68 and 
VA64. The Berghmans point was found to be around 13% w/w of MFA in both MFA-
EPO and MFA-SLP systems. However, the metastable zone is narrow in case of MFA-
SLP system, indicating that a small fluctuation in the formulation can lead to phase 






Figure 18: Thermodynamic phase diagrams of MFA in the four polymers showing the 
solubility curve, miscibility curve, and the glass transition curve.  The arrows 






4.8. Process Optimization of HME Using Material Sparing DSC Method 
The critical elements in preparing ASDs using HME are the drug loading, 
temperature of the heating zones, the screw design, the screw speed (residence time) and 
the feeding rate of the input material. If the processing temperature is high, it can result in 
degradation of certain drugs which is detrimental if the degradant is toxic.  If the 
processing temperature is low, insufficient heat energy is available for the crystalline 
drug to convert into amorphous form, resulting in residual crystallinity. Therefore, it is 
important to optimize the processing conditions so that minimum drug degradation and 
minimum residual crystallinity is present in the ASDs. This can be done by understanding 
the interdependency of drug load, processing temperature and the HME screw speed on 
the residual crystallinity and drug degradation. However, it requires a lot of experiments 
and large amounts of drug to run these experiments. Therefore, there is a need to develop 
a material sparing method to determine the ideal processing conditions for HME, with 
minimum number of experiments. One such approach could be the use of differential 
scanning calorimeter (DSC), which is a commonly used analytical technique. Like HME, 
the thermal energy applied while heating the sample in a DSC breaks the crystal lattice of 
the drug then the drug becomes miscible in the polymeric matrix depending on its affinity 
with the polymer. Therefore, DSC has a potential to be a miniature, material sparing, 
screening tool to determine the optimum processing conditions in the preparation of 
ASDs using HME. The objective of the following work was to optimize the processing 
conditions of HME using DSC and response surface methodology. For this purpose, the 
effect of drug loading, heating rate and temperature on the residual crystallinity and 




using film casting method, hot-stage microscopy and TGA to determine the range of 
experimental conditions. Based on this information, a Box-Behnken experimental design 
was used to create a total of fifteen experimental runs with an ability to understand the 
main effect and the interaction effect between the independent parameters; drug loading 
(X1), heating rate (X2) and temperature (X3), and the dependent variables residual 
crystallinity (Y1) and drug degradation (Y2).  
 
4.8.1. Results of Initial Screening Experiments to Setup the Experimental Design 
The initial screening was performed to determine the ideal conditions for the 
experimental design. The polarized light microscope images of various films prepared 
using the film casting method is shown in Figure 19. It was observed that at drug loading 
of less than 40% w/w drug loading (Fig. 19a) a homogeneous film with very traces of 
MFA crystals were observed. At 45% w/w drug loading (Fig. 19b), small amounts of 
MFA crystals were observed, indicating recrystallization. In case of 50% w/w drug 
loading (Fig. 19c), large drug rich regions were observed on the film indicating that MFA 
recrystallized from the polymeric matrix of EPO. Based on the results from film casting 
experiments, it could be concluded that a maximum of 40% w/w MFA was miscible with 
EPO without undergoing recrystallization at room temperature. Alshehri et al. reported 
that a maximum of 25% MFA was miscible with EPO when processed using HME (73). 
In another study, Kojima et al. reported that a maximum of 24% MFA was miscible with 
EPO when processed using cryo-milling (74). The higher drug loading achieved in the 
case of film casting can be attributed to its high mixing efficiency as compared to HME 




dispersed in a common solvent resulting in higher mixing efficiency. In the case of HME 
and cryo-milling, the mixing efficiency was much lower resulting in drug-polymer 
dispersions with regions having higher drug concentration. These drug rich regions 
initiate nucleation, followed by crystal growth and recrystallization of drug. Therefore, it 
is safe to assume that the maximum drug loading achieved using HME or cryo-milling is 
always lower than the film casting method. Hence, 40% w/w drug loading was taken as 
the higher level of drug loading in the experimental design. The lower level of drug 
loading was taken as 20% w/w based on the published literature and to ensure that a wide 
range of responses were observed from the experimental design. Based on the results of 
film casting method, the powder blend containing 40% w/w drug loading was prepared in 
a mortar and pestle and analyzed under hot stage microscopy. Figure 19 shows the hot 
stage microscopy images of 40% drug loading at various temperatures. It was observed 
that at around 60 °C (Fig. 19d), EPO started to transform into rubbery state. At around 
100 °C (Fig. 19e), EPO completely transformed into a rubbery state exposing the MFA 
crystals. At around 140 °C (Fig. 19f), a homogeneous mixture was observed indicating 
that MFA crystals dissolved into the polymeric matrix of EPO. Although MFA has a high 
melting point of 231° C, it was miscible in EPO at much lower temperature due to a 
phenomenon called melting point depression. Once the EPO molecules undergo glass 
transition, the higher mobility of EPO molecules reduces the chemical potential of MFA 
crystals, thereby reducing the total energy required to break the crystal lattice. This 
results in the melting of MFA at much lower temperatures than its melting point (75). 
The results of the hot stage microscopy (HSM) suggest that the minimum temperature at 




140 °C. Therefore, it was taken as the lower level for temperature (X3) in the 
experimental design. 
The higher level for the temperature and the experimental level for heating rate 
were determined using TGA analysis. Initially, the % weight loss of pure EPO was 
determined for upto 250 °C to ensure that the polymer was stable at such high 
temperature. It was observed that less than 2% of EPO degraded at around 250 °C, which 
showed that EPO was stable at ahigh temperature. The powder blends containing 40% 
w/w MFA-EPO were analyzed using TGA at various heating rates. Based on the TGA 
data, it was observed that the rate of degradation of MFA was dependent on the heating 
rate of the TGA. Since EPO was proved to be stable at a high temperature, any weight 
loss observed during the TGA analysis could be attributed to the degradation of MFA. It 
was evident from the data that most of the MFA underwent degradation at around 220 
°C. Therefore, the higher level for the heating temperature (X3) was taken as 220 °C in 
the experimental design. The relationship between the TGA heating rate and the % 
weight loss of MFA at 220 °C is shown in Figure 20. It was observed that at heating rates 
of 0.1 °C/min to 1 °C/min, the % weight loss of MFA was more than 60%. As the heating 
rate increased from 1 °C/min to 10 °C/min, the % weight loss decreased exponentially. 
At higher heating rates of 10 °C/min to 20 °C/min, the % weight loss remained low at 
around 10%. Since a significant amount of weight loss took place between 1 °C/min to 
10 °C/min, these values were taken as the lower lever and higher level for the heating rate 





Figure 19: Polarized light microscopy images of films prepared by film casting method: 
40% w/w drug loading (a), 45% w/w drug loading (b), 50% w/w drug loading 
(c). Hot stage microscopy images of 40% w/w MFA-EPO powder blends at 60 







Figure 20: Relationship between % weight loss (drug degradation) at 220 °C and heating 

























4.8.2. Box-Behnken Design and Observed Responses 
The fifteen experimental runs along with the observed responses are given in 
Table 6. Within the studied experimental domain, the minimum value of residual 
crystallinity (Y1) was found to be 1.0 ± 0.3% and the maximum value was found to be 
33.5 ± 4.1%. A minimum % drug degradation (Y2) was found to be 3.5 ± 0.7% and the 
maximum value was found to be 26.8 ± 4.2%. Based on the obtained experimental data, 
it was difficult to determine the effect of each independent parameters on the dependent 
parameters. Therefore, the observed responses were fitted into various models (linear, 
cubic and quadratic) to obtain the best fit. It was found that all the responses were fitted 
into a second-order quadratic polynomial model. The model coefficients that were not 
significant were eliminated and the significant coefficients including the interaction terms 
were defined according to the following quadratic equations (Eqs. 35 and 36):  
 
Residual crystallinity (Y) = 15.57 + 8.61X + 3.28X − 8.34X + 2.48XX − 1.16XX −
3.93XX + 0.34X − 2.79X + 0.19X                                                                  (Eq. 35) 
 
Drug degradation (Y) = 8.67 + 2.01X − 3.89X + 7.60X − 0.005XX + 2.68XX −






Table 6: Box-Behnken experimental design showing the fifteen experimental runs and 
the observed responses 












1 30 5.5 180 16.3 ± 2.3   8.5 ± 2.1 
2 30 5.5 180 14.9 ± 1.8   7.1 ± 1.4 
3 40 5.5 140 33.5 ± 4.1   3.7 ± 0.4 
4 30 1 220   5.7 ± 0.9 26.8 ± 4.2 
5 30 10 140 28.1 ± 4.8   3.5 ± 0.7 
6 30 1 140 14.3 ± 2.2   8.4 ± 2.3 
7 40 5.5 220 14.3 ± 5.1 23.5 ± 4.2 
8 30 5.5 180 15.5 ± 2.2 10.4 ± 1.5 
9 40 1 180 16.5 ± 3.1 16.0 ± 2.8 
10 20 10 180   4.8 ± 1.2   5.3 ± 1.8 
11 20 5.5 140 15.6 ± 3.3   3.5 ± 1.3 
12 40 10 180 28.6 ± 4.5   7.8 ± 2.2 
13 20 1 180   2.6 ± 0.4 13.5 ± 4.2 
14 20 5.5 220   1.0 ± 0.3 12.6 ± 3.8 
15 30 10 220   3.8 ± 0.7 17.0 ± 2.2 
 






The summary of ANOVA results is shown in Tables 7 and 8. It was found that the 
model was significant for all the studied responses. The lack of fit was found to be not 
significant which shows that the experimental results had excellent goodness of fit. Based 
on the experimental coefficients (Eqs. 35 and 36), it can be observed that drug load (X1) 
had a significant positive effect and temperature (X3) had a significant negative effect on 
residual crystallinity (Y1). It means, an increase in drug load (X1) results in increase in 
residual crystallinity (Y1) while increase in temperature (X3) results in decrease in 
residual crystallinity (Y1). Also, the combination of heating rate and temperature (X2X3) 
was found to have a negative effect on residual crystallinity (Y1). In the case of % 
degradation, temperature (X3) was found to have a positive effect and the heating rate 
(X2) was found to have a negative effect. It indicates that an increase in the temperature 
and decrease in the heating rate increased the % drug degradation (Y2). To exhibit the 
effect of independent factors on the dependent factors, response surface plots and contour 






Table 7: Summary of results from ANOVA showing the residual sum of squares, F 
statistics and the lack of fit test results 
Parameters SS DF MS F value P Value Significance 
Residual crystallinity (%) 
Model 1356.42 9 150.71 105.88 <0.0001 significant 
Residual 7.12 5 1.42 - - 
 
Lack of fit 6.13 3 2.04 4.14 0.2006 not significant 
Pure error 0.9867 2 0.4933 - -   
Total 1363.54 14 - - -   
Drug degradation (%) 
Model 700.98 9 77.89 33.57 0.0006 significant 
Residual 11.60 5 2.32 - -   
Lack of fit 6.12 3 2.04 0.7431 0.6137 not significant 
Pure error 5.49 2 2.74 - -   






Table 8: Statistical analysis of the observed responses showing the best-fit model, 
regression coefficient and coefficient of variation (% CV) 
Responses Model R2 Adj R2 Pred R2 SD % CV 
% Residual 
crystallinity (Y1) 
Quadratic 0.9948 0.9854 0.9264 1.19   8.30 
% Drug 






4.8.3. Response Surface Plots and Contour Plots 
Response surface plots exhibit presence of cause and effect relationship among 
the studied factors for providing enhanced product and process understanding. The 
contour plots and response surface plots indicating the effect of the independent 
parameters on the residual crystallinity (Y1) are shown in Figures 21 and 22. 
  
4.8.4. Effect of Independent Parameters on Residual Crystallinity 
The contour plot representing the effect of the final heating temperature of the 
DSC and the heating rate on the residual crystallinity is shown in Figure 21a. It can be 
observed that higher heating rate and lower temperature, increased the % residual 
crystallinity. When the heating rate is high, the total time and energy provided to the 
sample will be low. As a result, not enough energy is available to break the crystal lattice 
of the drug thereby resulting in higher % residual crystallinity. Interestingly, the 3D 
response surface plot (Fig. 21b) shows that at lower heating rate, the temperature did not 
have any effect on the % residual crystallinity. However, at higher heating rates, the % 
residual crystallinity decreased linearly with an increase in the temperature.  The contour 
plot representing the effect of the temperature and the drug load on the residual 
crystallinity is shown in Figure 21c. It was observed that high residual crystallinity was 
obtained when the drug load was high, and the temperature was low. On the other hand, 
lower values of residual crystallinity were observed at low drug load and high 
temperature. When the drug load is high, higher amount of heat energy is required to 
break the crystal lattice of MFA. To provide such amount of heat, the MFA-EPO 




provided, the MFA particles remain in the crystalline form resulting in higher % residual 
crystallinity. This shows the importance of the processing parameters on the residual 
crystallinity (76). The 3D response surface plot (Fig. 21d) shows that at low 
temperatures, the % residual crystallinity increased linearly with an increase in the drug 
loading. This shows that when an increase in the processing temperature is a limitation 
for HME processing, then the drug load should be decreased to lower the residual 
crystallinity.  The contour plot representing the effect of the heating rate and the drug 
load on the residual crystallinity is shown in Figure 21e. At high drug load and high 
heating rate, high residual crystallinity was observed.  The 3D response surface plot (Fig. 
21f) shows that at low heating rate, the drug load did not show any significant increase in 
the residual crystallinity. However, at high heating rate, the drug load significantly 
increased the residual crystallinity. This is due to the lower amount of heat energy 








Figure 21: 2D-contour plots and 3D response surface plots showing the effect of 




4.8.5. Effect of Independent Parameters on Drug Degradation 
The contour plot representing the effect of the temperature and the heating rate on 
the drug degradation is shown in Figure 22a. It was observed that at lower heating rate 
and high temperature, the drug degradation was high. This was due to the excess thermal 
energy provided to the drug-polymer dispersions which resulted in breakage of the crystal 
lattice of MFA and an increase in the molecular mobility. This exposed the carboxylic 
acid group (-COOH) of the molecule which underwent decarboxylation.  The results 
were in accordance with the thermal decomposition of MFA observed by rapid ESI-MS 
method as reported by Zhou and Gilpin (67).  The authors reported that when MFA was 
dissolved in a mobile phase consisting of methanol-water (80:20 v/v) and subjected to 
thermal degradation between 130 °C and 230 °C, MFA was converted to MFA-H+ which 
was completely converted to the final decomposition fragment with an m/z value of 224 
at a temperature of 230 °C. The 3D response surface plot (Fig. 22b) shows that at lower 
heating rate, the temperature has a significant effect on the drug degradation. On the other 
hand, at low temperatures, the % degradation remained constant with increase in the 
heating rate. The contour plot presenting the effect of the temperature and the drug load 
on the degradation is shown in Figure 22c. It was observed that high drug degradation 
was obtained when the drug load and the temperature were high. The 3D response 
surface plot (Fig. 22d) shows that at low temperature, the drug degradation was low and 
remained constant with an increase in the drug load. However, at high drug load, the 
degradation increased significantly with an increase in the temperature. The contour plot 
representing the effect of the heating rate and the drug load on the drug degradation is 




observed. The 3D response surface plot (Fig. 22f) also show that high drug load and low 
heating rate resulted in high drug degradation. However, at lower drug load, the drug 
degradation was low and did not change with an increase in the heating rate. Based on the 
response surface plots and the contour plots, it is evident that all the three independent 









Figure 22: 2D-contour plots and RSA plots showing the effect of experimental variables 




4.8.6. Establishment of Design Space 
The selection of the optimum formulation was carried out using the numerical and 
the graphical optimizations. Initially, the target values for residual crystallinity and drug 
degradation were assigned and the numerical optimization was performed to determine 
the possible solutions and the desirability values. The optimized batch was selected from 
among the solutions obtained for the criteria, i.e. maximu drug load, minimum % residual 
crystallinity, and  minimum % drug degradation. The solutions with desirability close to 
one was considered as the optimum formulation. The results of the numerical 
optimization are shown in Table 9.  
The optimum processing conditions were also selected using an overlay plot using 
the same constraints as that of numerical optimization. Figure 23 shows the overlay plot 
between the processing parameters with the design space indicated in yellow shade. The 
contour lines indicate the boundary lines set for each of the responses. According to the 
overlay plot, it was found that when powder blend containing 20% w/w drug load was 
heated at a rate of 5.5 °C/min to the heating temperature of 146 °C, the resulting drug-
polymer dispersion contained residual crystallinity of 13.6% with drug degradation of 
3.8%. Once the optimum processing conditions was determined, the experimental design 
was validated by preparing six checkpoint formulations. The experimentally observed 
values of the six checkpoint formulations were compared with the predicted values from 






Table 9: Results of the numerical optimization performed using desirability 





















































































0.000 -0.996 27.500 3.500 0.531 
 
 








Figure 23: Overlay plot showing the design space established using graphical 
optimization for minimum residual crystallinity, minimum degradation and 






4.8.7. Validation of Experimental Design 
The design space was validated by preparing six confirmatory formulations within 
the experimental domain. The linear correlation plots and the residual plots of all the 
validation batches are shown in Figure 24. The values of bias were found to be 0.018 and 
-0.61 for residual crystallinity and drug degradation, respectively (Table 10). Low values 
of bias close to zero (‘0’) indicate that the model was unbiased. The prediction error was 
found to be 5.72 and 9.94 for residual crystallinity and drug degradation, respectively. 
Low values of bias and the prediction error indicate the high degree of predictability of 















Residual crystallinity (%) Degradation (%) 
Pred. Obs. Residual Pred. Obs. Residual 
25 5 180 11.08 12.1±1.4 0.9815 7.98 8.86±0.28 16.1 
25 10 200 4.80 5.4±0.69 0.6291 9.37 9.83±0.97 12.81 
20 1 140 7.16 7.9±0.58 0.7333 9.09 10.53±0.78 -4.76 
20 5 200 3.84 4.6±0.41 0.7885 9.77 10.46±1.48 -18.64 
40 3 140 27.96 25.5±3.9 -2.3992 4.83 5.66±1.06 -15.04 
40 10 180 27.48 26.9±2.31 -0.6208 8.78 9.73±1.93 5.83 
Bias 0.018 -0.61 









Figure 24: Linear and residual plots between the observed and the predicted values of   






4.8.8. Hot Melt Extrusion and Vacuum Compression Molding Samples 
 Based on the design space obtained from the DSC experiments, 20% w/w MFA-
EPO dispersions were prepared using HME and VCM. The drug loading and final 
heating temperature can be correlated directly with the HME process parameters. 
However, the heating rate in DSC cannot be correlated to the screw speed in HME. 
Therefore, three different samples were prepared at three different screw speeds (i.e., 50 
rpm, 100 rpm and 150 rpm) to see the effect of screw speed on residual crystallinity and 
% degradation. The HME filaments prepared at a screw speed of 100 rpm and 150 rpm 
along with the VCM sample prepared at 150 °C are shown in Figure 25.  The drug-
polymer dispersions processed in HME at a screw speed of 50 rpm had high torque and 
did not get extruded. The HME filaments obtained at a screw speed of 100 rpm and 150 
rpm looked clear without any visible signs of MFA crystals. However, the filaments 
obtained at a screw speed of 100 rpm did show slight discoloration. This could be due to 
the degradation of drug or the polymer. The MFA-EPO dispersions processed in VCM at 
150 °C for 3 minutes resulted in a clear dispersion with no evidence of phase separation. 
To further confirm that the MFA-EPO dispersions prepared using HME and VCM 
formed a homogeneous dispersion, DSC analysis was done, and the results are shown in 
Figure 26. In all the three samples, no endothermic peak of the drug was observed 
indicating that the MFA converted into amorphous form. Also, a single Tg was observed 
at around 50 °C which shows that MFA was molecularly dispersed in EPO and there was 
no phase separation. However, the HPLC analysis of the samples showed that 5% of 
MFA was degraded in the VCM samples. In the case of HME samples, no degradation 




in samples processed at 100 rpm (Table 11). This marked increase in MFA degradation at 
100 rpm can be attributed to an increase in the residence time as compared to the samples 
processed at 150 rpm. This shows the significance of the screw speed as an important 
process parameter in HME. Also, it should be noted that the samples processed in HME 
are subjected to both thermal and mechanical energy as compared to the samples 
processed in DSC where only thermal energy is provided. This is the reason why no 
residual crystallinity was observed in the HME filaments as compared to the samples 
prepared in DSC. To further confirm that there is no residual crystallinity in the HME and 
VCM samples, X-ray diffraction analysis was performed, and the results are shown in 
Figure 27. The X-ray diffractogram of pure MFA revealed characteristic crystalline peaks 
at 21.3° and 26.3° along with some crystalline peaks of lower intensity at 13.4°, 14.9°, 
15.5°. These results suggest that pure MFA obtained from the vendor was a mixture of 
form I and form II (59, 77). The X-ray diffractograms of drug-polymer dispersions 
prepared using HME and VCM showed amorphous halo with no characteristic peak of 
MFA. The results of XRD were in accordance to the DSC results and confirmed that 









Figure 25: MFA-EPO (20% w/w) ASDs  prepared using hot melt extrusion at a screw 
speed of 150 rpm and 100 rpm and vacuum compression molding (VCM) 
prepared at 150 °C. The drug-polymer blends processed in HME at a screw 









Figure 26: DSC thermograms of 20% w/w drug loaded MFA-EPO dispersions prepared 
using HME and VCM. A single glass transition temperature was observed in 








Figure 27: Powder X-ray diffraction scans of pure mefenamic acid, vacuum compression 
molding (VCM) sample, and hot-melt extrusion (HME) filaments processed 






Table 11: Residual crystallinity and drug degradation of VCM and HME samples 
Sample Residual Crystallinity (%) Degradation (%) 
VCM NA 5.0 
HME – 100 rpm NA 7.51 
HME – 150 rpm NA NA 
 







4.9. Effect of Temperature and Relative Humidity on Recrystalization 
4.9.1. Determination of Recrystallization using DSC 
The samples prepared using the heat molding method were analyzed using DSC 
(DSC 6000, Perkin Elmer, USA) to ensure that crystalline MFA was completely 
converted into an amorphous form. There was no endothermic peak observed in the DSC 
scans indicating that the MFA crystals were completely converted into amorphous form 
after the heat molding process. The samples were then stored at various temperature and 
relative humidity conditions and the DSC scans were performed at various time points. 
The DSC scans of 40% w/w drug loaded MFA-EPO solid dispersions at 40 °C and 75% 
RH are shown in Figure 28. It was observed that the value of heat of fusion increased 
with time indicating recrystallization. Figure 29 shows the rod shaped crystals of MFA 
observed under a microscope. This indicates that recrystallization of MFA takes place in 
a rod shaped with a dimensionality value, n=2. This helps to determine the 











Figure 28: DSC thermograms showing the recrystallization of MFA over the period of 







Figure 29: Rod shaped crystals of MFA recrystallized from acetone. The magnified 





4.9.2. Effect of Temperature on Recrystallization of MFA in EPO Matrix 
The heat of fusion values (ΔHf) of MFA observed at various time points at 
various temperatures and a constant relative humidity of 75% RH are shown in Table 12. 
The plots between the relative crystallinity and time at 75% RH and various temperatures 
are shown in Figure 30. At all the studied temperature ranges, it was observed that the 
relative crystallinity increased rapidly and then became constant. Earlier publications 
have reported a characteristic ‘S’ shaped curve for recrystallization of drugs in which the 
recrystallization rate was low initially, due to nucleation, then rapid recrystallization due 
to an increase in the nucleation sites and crystal growth followed by a flat phase that 
corresponds to the decrease in the nucleation sites. However, in the present study, initial 
nucleation sites were not observed. This could be due to the non-glass forming ability of 
MFA which undergoes recrystallization when the samples are cooled. This resulted in the 
formation of nucleation sites before the set experimental timelines (8 hr). However, rapid 
recrystallization was observed at a later stage due to an increase in the nucleation sites. 
The values of recrystallization rate, k, and the dimensionality constant, n, determined at 
75% RH and various temperatures are given in Table 13. A plot of recrystallization rate 
constant, k  and temperature is shown in Figure 31. When n>0, the value of k at 25 °C, 40 
°C and 60 °C was observed as 3.58×10-3 hr-n, 3.59×10-3 hr-n and 6.47×10-3 hr-n, 
respectively. However, at 70° and 80 °C, the values increased to 21.05×10-3 hr-n and 
44.04×10-3 hr-n, respectively. This exponential increase in the value of k can again be 
attributed to an increase in the molecular mobility above the glass transition temperature, 
Tg. When non-linear regression analysis was performed at n=2, the value of k at 25 °C, 40 




2.50×10-3 hr-n and 7.25×103 hr-n, respectively. By comparing the values of k from both the 
analysis, it can be inferred that the rate of recrystallization is low at lower temperature 
and increases exponentially above the Tg of the drug-polymer dispersions. Using non-
linear regression analysis, higher values of recrystallization rate constant, k, were 
predicted using the dimensionality constant, n, as >0 as compared to the values obtained 
when n was fixed as 2. This was due to the flip-flop effect observed during non-linear 
regression analysis (80). The average value of n predicted when n>0 was found to be 1.44 
which is close to 2. This indicates that MFA recrystallizes as rod shaped crystals inside 






Table 12: Values of heat of fusion of MFA recrystallized from the samples at various 
temperatures and 75% RH. 
Time 
(hr) 
Heat of Fusion (ΔHf) J/g 
25 °C/ 75% 
RH 
40 °C/ 75% 
RH 
60 °C/ 75% 
RH 
70 °C/ 75% 
RH 
80 °C/ 75% 
RH 
8 - - 9.85 ± 0.45 14.69 ± 1.85 16.40 ± 1.77 
12 - 6.57 ± 0.56 11.09 ± 2.90 15.18 ± 2.40 22.43 ± 0.52 
18 6.8 ± 0.58 7.49 ± 0.37 12.26 ± 3.45 24.49 ± 3.39 25.16 ± 2.19 
24 7.1 ± 0.70 7.76 ± 0.30 16.46 ± 1.17 30.73 ± 1.90 36.23 ± 9.12 
48 9.95 ± 0.88 8.95 ± 0.54 24.67 ± 2.88 38.50 ± 2.68 35.28 ± 6.44 
72 13.40 ± 1.77 10.73 ± 0.85 31.33 ± 1.09 44.75 ± 2.60 40.05 ± 4.46 
96 14.58 ± 1.04 13.92 ± 0.86 39.60 ± 1.29 46.83 ± 1.20 40.60 ± 5.99 
120 17.04 ± 0.86 17.98 ± 1.46 40.20 ± 2.58 48.25 ± 2.68 40.65 ± 2.54 
144 17.81 ± 1.97 20.95 ± 1.43 43.24 ± 0.90 48.31 ± 3.79 40.83 ± 2.66 
168 21.90 ± 1.25 21.13 ± 0.79 44.74 ± 0.90 50.94 ± 4.31 41.22 ± 2.45 
192 23.32 ± 1.06 21.98 ± 0.13 45.96 ± 5.13 51.16 ± 4.26 41.70 ± 2.06 
216 24.01 ± 1.54 25.68 ± 1.16 45.59 ± 2.57 51.01 ± 2.70 42.15 ± 3.52 
240 23.94 ± 1.54 26.28 ± 0.94 46.10 ± 3.98 52.09 ± 2.08 42.17 ± 3.25 
264 24.53 ± 1.34 26.56 ± 1.02 45.98 ± 2.96 51.83 ± 1.84 41.45 ± 2.42 









Figure 30: Relative crystallinity, α(t) as a function of time for 40% w/w drug loaded 




Table 13: The values of recrystallization rate constant, k and dimensionality constant, n 
of MFA at various temperatures and 75% RH.  
Stability 
conditions 
n > 0 n = 2 
k × 103 (hr-n) n R2 k × 103 (hr-n) R2 
25 °C / 75% RH   0.54 ± 0.89 1.89 ± 0.35 0.9225 0.31 ± 0.08 0.9139 
40 °C / 75% RH    3.75 ± 2.56 1.47 ± 0.19 0.9452 0.66 ± 0.10 0.9348 
60 °C / 75% RH   8.70 ± 4.10 1.37 ± 0.14 0.9689 1.10 ± 0.20 0.9522 
70 °C / 75% RH 23.99 ± 3.73 1.27 ± 0.04 0.9792 2.04 ± 0.45 0.9257 
80 °C / 75% RH 31.64 ± 6.97 1.43 ± 0.08 0.9738 7.65 ± 0.76 0.9268 
 









Figure 31: Relationship between the recrystallization rate constant, k, and temperature at 





4.9.3. Arrhenius Plot of Recrystallization as a Function of Temperature 
The Arrhenius plot was constructed by ploting the values of log k vs 1/T that 
revealed that the crystallization rate increased exponentially with temperature, T, within 
the temperature range studied implying that the Arrhenius equation expresses the 
temperature dependence of recrystallization rate (Fig. 32). The recrystallization activation 
energy, ΔEa, was determined from the slope of the linear regression of ln k and 1/T. The 
activation energy allows the prediction of recrystallization kinetics at temperature outside 
the experimental range.  The value of activation coefficient, ΔEa, was found to be 63,024 
J/mol (15.06 Kcal/mol) when n>0 and 44,828 J/mol (10.74 Kcal/mol) when n=2. This 









Figure 32: Arrhenius plot of crystallization rate constant, k, as a function of inverse of 
temperature, 1/T for 40% w/w drug loaded MFA-EPO dispersions.
y = -7.5801x + 18.19
R² = 0.9664


















4.9.4. Effect of Relative Humidity on Recrystallization of MFA in EPO Matrix 
The values of heat of fusion, ΔHf, of MFA observed at various time points at 
various relative humidity conditions and a constant temperature of 60 °C are shown in 
Table 14. The plots between the relative crystallinity and time at 60 °C and various 
relative humidity conditions are shown in Figure 33. At the relative humidity range 
studied, it was observed that the relative crystallinity increased rapidly and then became 
constant. The experimental values correlated well with the kinetic model at all the 
relative humidity conditions except at 11% RH where the kinetic model overpredicted the 
relative crystallinity (black squares as outliers in Fig. 33). Similar to the effect of 
temperature, no nucleation sites were observed in the samples stored at various relative 
humidity conditions. The values of recrystallization rate, k, and the dimensionality 
constant, n, determined at 60 °C and various relative humidity conditions are given in 
Table 15. A plot of recrystallization rate constant, k, and temperature is shown in Fig. 34. 
When non-linear regression analysis was performed at n>0, the values of k at 11% RH, 
22% RH, 32% RH, 60% RH and 75% RH were 2.02×10-3 hr-n, 4.98×10-3 hr-n, 5.03×10-3 
hr-n, 5.58×10-3 hr-n and 6.47×10-3 hr-n, respectively. When non-linear regression analysis 
was performed at n=2, the values of k at 25 °C, 40 °C, 60 °C, 70 °C and 80 °C were 
0.19×10-3 hr-n, 0.53×10-3 hr-n, 0.74×10-3 hr-n, 0.75×10-3 hr-n and 0.71×10-3 hr-n, 
respectively. Upon comparing the values of k by both the analyses, it can be inferred that 
the rate of recrystallization was low at 11% RH and increased at 32%RH, 60% RH and 
75% RH conditions. As described earlier, the experimental data at 11% RH did not fit 




Table 14: Values of heat of fusion of MFA recrystallized from the samples at 60 °C 









60 °C/60% RH 60 °C/75% RH 
8 6.7 ± 0.5 11.9 ± 2.0 8.1 ± 0.8 9.13 ± 1.64 9.85 ± 0.45 
12 7.7 ± 0.5 11.6 ± 1.2 7.5 ± 0.2 10.00 ± 0.34 11.09 ± 2.90 
18 10.1 ± 1.3 12.3 ± 1.6 8.0 ± 1.1 11.03 ± 1.30 12.26 ± 3.45 
24 10.1 ± 0.8 14.7 ± 1.3 18.0 ± 1.4 15.09 ± 1.66 16.46 ± 1.17 
48 15.1 ± 2.7 28.6 ± 3.6 26.3 ± 2.6 22.81 ± 0.99 24.67 ± 2.88 
72 20.6 ± 2.4 35.6 ± 4.7 29.7 ± 0.1 28.96 ± 0.84 31.33 ± 1.09 
96 22.2 ± 0.8 36.6 ± 2.9 34.7 ± 2.9 36.51 ± 1.99 39.60 ± 1.29 
120 29.3 ± 1.4 38.1 ± 4.2 37.4 ± 1.4 37.15 ± 0.83 40.20 ± 2.58 
144 30.7 ± 0.7 38.4 ± 2.7 39.2 ± 2.2 40.00 ± 1.09 43.24 ± 0.90 
168 37.4 ± 0.5 40.9 ± 3.9 40.9 ± 2.4 41.40 ± 4.41 44.74 ± 0.90 
192 42.2 ± 2.8 43.7 ± 4.0 41.5 ± 3.6 42.12 ± 1.55 45.96 ± 5.13 
216 43.7 ± 0.9 43.7 ± 3.1 42.3 ± 2.7 42.02 ± 2.32 45.59 ± 2.57 
240 44.1 ± 4.5 45.3 ± 3.9 42.9 ± 1.8 42.32 ± 1.25 46.10 ± 3.98 
264 44.4 ± 3.3 44.8 ± 4.8 43.2 ± 4.2 42.30 ± 1.40 45.98 ± 2.96 
288 43.2 ± 4.2 45.5 ± 3.2 43.9 ± 3.9 42.94 ± 2.04 46.73 ± 3.88 
 








Figure 33: Relative crystallinity, α(t), as a function of time for 40% w/w MFA-EPO 




Table 15: Values of recrystallization rate constant, k, and dimensionality constant, n, of 
MFA at 60 °C temperature and various relative humidities 
Stability 
conditions 
n > 0 n = 2 
k × 103 (hr-n)   n R2 k × 103 (hr-n) R2 
11% RH/ 60 °C   5.06 ± 4.87 1.29 ± 0.20 0.8588 0.16 ± 0.03 0.8322 
22% RH/ 60 °C   5.12 ± 2.89 1.49 ± 0.13 0.9045 0.55 ± 0.08 0.8751 
32% RH/ 60 °C   5.77 ± 1.94 1.51 ± 0.07 0.9286 0.60 ± 0.11 0.8732 
60% RH/ 60 °C   6.41 ± 3.45 1.43 ± 0.16 0.9694 0.93 ± 0.17 0.9130 
75% RH/ 60 °C   8.70 ± 4.10 1.37 ± 0.14 0.9690 1.10 ± 0.20 0.9522 
 







Figure 34: Plot showing relationship between the recrystallization rate constant, k, and 





4.9.5. Effect of Relative Humidity on Recrystallization of MFA in EPO Matrix at 
Room Temperature 
To understand the effect of relative humidity on recrystallization of MFA at room 
temperature, 25° C, the MFA-EPO (40% w/w) dispersions were further stored at 32±5% 
RH and 75±5% RH and a temperature of 25±2 °C. The amount of MFA recrystallized 
from the drug-polymer dispersions at different time points was determined using DSC 
and the recrystallization rate constant was estimated using modified Avarami equation. 
The heat of fusion (ΔHf) values of MFA recrystallized at different relative humidities of 
11%, 32% and 75% and temperature of 25 °C were given in Table 16. By comparing the 
heat of fusion values at room temperature and at 60 °C, it can be observed that after 288 
hrs, the values of ΔHf at 25 °C are significantly lower than that observed at 60 °C. This 
shows that recrystallization of MFA at room temperature is slower than that observed at 
60 °C, which is close to the glass transition temperature of the drug-polymer system. The 
rate of recrystallization was calculated using non-linear regression analysis. The 
relationship between the reltive crystallinity and time is show in Figure 35. It can be 
observed that the relative crystallinity, α(t), was observed to be increasing linearly rather 
than exhibiting the characteristic ‘S’ shaped curve that was observed at higher 
temperatures. This show that the rate of recrystallization is slow and the drug-polymer 
system did not undergo nucleation, followed by crystal growth. In such cases, the data 
used to estimate the recrystallization rate will not fit the modified Avarami model. This is 
evident from the values of rate of recrystallization, k observed at various relative humidty 
and at room temperature as shown in Table 17 and Figure 36. The overestimated values 




Table 16: Values of heat of fusion of MFA recrystallized from the samples stored at 25 
°C temperature and various relative humidities 
Time (hr) 11% RH/ 25 °C 32% RH/ 25 °C 75% RH/ 25 °C 
8 7.47 ± 1.04 11.00 ± 2.58 NA 
12 8.10 ± 0.83  13.85 ± 2.60 NA 
18 9.86 ± 1.57 13.57 ± 4.18 6.83 ± 0.58 
24 10.51 ± 0.40 16.34 ± 4.05 7.09 ± 0.70 
48 11.67 ± 2.95 17.03 ± 3.69 9.95 ± 0.88 
72 16.80 ± 2.58 16.97 ± 4.70 13.40 ± 1.77 
96 17.54 ± 2.37 17.60 ± 4.71 14.58 ± 1.04 
120 15.87 ± 1.43 19.51 ± 2.79 17.04 ± 0.86 
144 17.94 ± 2.69 17.96 ± 2.05 17.81 ± 1.97 
168 15.31 ± 1.65 20.26 ± 2.11 21.90 ± 1.25 
192 15.45 ± 2.19 19.65 ± 0.94 23.32 ± 1.06 
216 16.14 ± 1.89 21.19 ± 1.51 24.01 ± 1.54 
240 17.08 ± 1.25 20.66 ± 1.35 23.94 ± 1.59 
264 16.67 ± 1.11 20.19 ± 1.27 24.53 ± 1.34 
288 18.22 ± 0.71 20.69 ± 1.41 24.72 ± 1.47 
 
All the experiments were performed in triplicate and the values are represented as mean ± 
SD (n=3) 






Figure 35: Plot of relative crystallinity, α(t), as a function of time for 40% w/w drug 






Table 17: The values of recrystallization rate constant, k, and dimensionality constant, n, 
of MFA at 25 °C temperature and various relative humidity conditions 
Stability 
conditions 
n > 0 n = 2 
k × 103 (hr-n)       n  R2 k × 103 (hr-n)   R2 
11% RH/ 25 °C   90.94 ± 21.4 0.86 ± 0.07 0.9652 0.16 ± 0.03 0.7301 
32% RH/ 25 °C   94.69 ± 65.14 1.17 ± 0.23 0.7584 0.60 ± 0.11 0.6685 
75% RH/ 25 °C   8.70 ± 4.10 1.37 ± 0.14 0.9690 1.10 ± 0.20 0.9522 
 









Figure 36: Relationship between the recrystallization rate constant, k and relative 
humidity at a dimentionality value of n = 2 and n > 0 at a temperature of 25 
°C. 
  













































4.9.6. Effect of Drug Loading on Recrystallization at 40 °C and 75% RH 
In earlier studies, the intermolecular interaction between the carboxylic acid of 
MFA and the aminoalkyl group of EPO was reported. Based on this, it is speculated that 
a stable system of MFA and EPO occurs within a stochiometric ratio; and when the drug 
loading is more than the stochiometric ratio, changes in the temperature and relative 
humidity cause phase separation. To test this hypothesis, the absolute amount of MFA 
recrystallized from the samples at various RH conditions was calculated. It was found 
that ~50% of the drug loading (40% w/w) recrystallized out irrespective of the RH 
conditions. That means, only 20% of MFA remained kinetically stable in the samples 
even at high relative humidity conditions. This value is close to the miscibility value of 
MFA in EPO predicted using thermodynamic phase diagrams. To further test this 
hypothesis, 30% MFA-EPO and 50% MFA-EPO samples were prepared and stored at 40 
°C and 75% RH. The enthalpy values were determined, and the extent of recrystallization 
were calculated for 45 day (Fig. 37). The % drug miscible in the polymeric matrix at 
various drug loading was calculated and it was observed that irrespective of the drug 
loading, around 25% of MFA was miscible in EPO matrix even when subjected to 









Figure 37: Plot demonstrating relationship between the % drug recrystallization and time 
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Figure 38: Effect of drug loading on drug miscibility. The red circles represent 






5. Summary and Conclusions 
The determination of ideal drug-loading and processing temperature for hot-melt 
extrusion to develop amorphous solid dispersions (ASDs) is challenging and often 
requires extensive experimentation.  While theoretical concepts of solubility parameters 
are reportedly used for initial screening of polymeric excipients for such formulations, 
their applicability is limited only to some drug-polymer combinations.  In the present 
investigations, therefore, thermodynamic aspects of mixing a non-glass forming drug, 
mefenamic acid (MFA), in four chemically distinct polymeric excipients with close 
values of Hansen and Hildebrand solubility parameters were studied. The rank order 
miscibility of MFA in the four polymeric carriers studied was estimated based on the 
difference in the values of solubility parameters, Δδ, between the drug and the polymer.  
Based on the difference in the values of the solubility parameters, Δδ, it was deduced that 
MFA will be miscible in all the four polymers studied.  However, the values of 
interaction parameters, χ, calculated from the melting point depression data suggested 
that while MFA would have good miscibility in EPO, SLP, and VA64, it would have 
poor miscibility in F68 despite a difference in the value of solubility parameter, ∆δ, less 
than 7 MPa0.5; a value of ∆δ < 7 MPa0.5 is considered to suggest good drug-polymer 
miscibility.  This suggests that the values of solubility parameters can lead to an 
overestimation of the degree of miscibility of the drugs and the polymeric excipients, and 
a difference in the value of solubility parameter, ∆δ, less than 7 MPa0.5 does not 
necessarily always indicate good drug-polymer miscibility.  Further, a systematic 
approach for the construction of thermodynamic phase diagrams and Gibbs free energy 




in the thermodynamic phase diagrams of MFA with various polymeric carriers studied 
showed that the predicted miscibility of MFA in both EPO and SLP was ~13% w/w, and 
in VA64 and F68 it was less than 5% w/w.  The upper critical solution temperature 
(UCST) of drug-polymer mixtures predicted from the Gibbs free energy plots showed 
that MFA will be miscible in EPO and SLP in all proportions at a processing temperature 
above 140 °C; in the case of VA64 and F68, the upper critical solution temperature 
(UCST) was above 200 °C.  The observations from the initial investigations thus lead to 
the conclusion that theoretical approaches, such as estimation of Hildebrand and Hansen 
solubility parameters and construction of the Bagley plot, should be used with caution in 
the assessment of drug-polymer miscibility, and the results from the thermodynamic 
phase diagrams and the Gibbs free energy plots will provide a better assessment tool for 
the selection of the ideal drug-loading and processing temperature for hot-melt extrusion 
process thereby reducing the total time and material required for the product and the 
process development. 
To determine the ideal processing conditions required for HME and to understand 
the relationship between the processing parameters, i.e. drug loading, residence time and 
the processing temperature, a material sparing DSC method was developed. In this work, 
the residual crystallinity and degradation of MFA in EPO polymeric matrix as a function 
of drug loading, DSC heating rate and DSC heating temperature was examined using 
Box-Behnken experimental design. The results showed that the studied process 
parameters had significant effect on the residual crystallinity and drug degradation. A 
quadratic relationship was obtained between the studied independent parameters and the 




increase in residual crystallinity, while an increase in temperature resulted in decrease in 
residual crystallinity. An increase in the temperature and decrease in the heating rate 
increased the drug degradation. Numerical and graphical optimization were used to 
predict the design space of the processing conditions which result in minimum residual 
crystallinity and minimum drug degradation. It was found that when a drug load of 20% 
w/w was processed at a heating rate of 5.5 °C/min and temperature of 146 °C, the 
resulting product had residual crystallinity of 13.6% and drug degradation of 3.8%. Based 
on the design space obtained from the experimental design, 20% w/w drug loaded MFA-
EPO dispersions were prepared using HME and VCM. The drug-polymer dispersions 
obtained using both HME and VCM did not show any signs of residual crystallinity of 
MFA. However, degradation of MFA was observed in VCM sample and the HME 
filaments processed at 100 rpm, but not at 150 rpm. This reiterates the significance of 
adjusting the screw speed during HME process.  
Once the optimized ASDs were obtained, their physical stability was determined by 
storing at accelerated conditions of 40 °C and 75% RH for three months. In practice, if 
recrystallization of the amorphous drug is observed after three months, the whole 
optimization process is performed again, resulting in loss of valuable time. Therefore, in 
the present investigation, a modified Avarami model was used to determine the physical 
stability of ASDs within an experimentally feasible time-frame. The rate of 
recrystallization calculated using the modified Avarami equation showed that 
temperature had a significant effect on the rate of recrystallization as compared to the 
relative humidity. The absolute crystallinity of MFA observed at three different drug 




RH. This showed that the amount of drug that was miscible in the polymeric carrier 
remained in the amorphous form even after subjecting to accelerated stability conditions. 
A work flow chart illustrating the formulation development process of ASDs using 
HME is  shown in Figure 39. In summary, selection of the ideal polymer and the 
processing temperature can be first determined using thermodynamic phase diagrams and 
Gibbs free energy plots. Once the ideal polymer and the miscibility of the drug in the 
polymer is determind, the HME process can first be designed using a DSC to determine 
the ideal drug-loading and processing temperature (i.e., the design space). Once the 
design space is identified, the optimization of screw configuration and screw speed can 
be performed by either in silico simulations and/or by conducting a few HME 
experiments.  Finally, the physical stability of the optimized ASDs can be determined at 
various temperatures and relative humidity conditions using the modified Avarami 
equation, thereby predict the shelf life of the ASDs. This approach significantly reduces 
the total number of experiments required to setup the HME process, thereby making the 







Figure 39: Flow chart summarizing the material-sparing approach for the formulation 
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